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ABSTRACT
A novel variant of autosomal dominant Alzheimer’s disease (AD) with additional
early neurological  signs and interesting neuropathological features occurred in a
large Finnish family with 23 affected individuals (16 men and 7 women) in four
successive generations.  The six surviving patients were personally examined, and
neurological records of nine deceased patients were evaluated.  In addition, eight
cases occurred in the early twentieth-century generations, for whom the medical
documents were lacking.  Electrophysiological investigations were available in eight
cases.  Neuroimaging had been performed on eleven patients, and in four patients
brain glucose metabolism was examined by positron emission tomography (PET).
The neuropsychological evaluation was based on tests of verbal and visual memory,
abstract thinking, and visuoconstructive and spatial functions.  Four surviving
patients were prospectively tested, and retrospective neuropsychological data were
collected from an additional four deceased patients.  Their possible psychiatric
symptoms were also evaluated.  Mean age at onset was 50.9±5.0 years (range 40 to
61).
Apart from dementia, the most striking clinical feature was gait disorder due to
spasticity of the lower extremities.  Spastic paraparesis appeared simultaneously or
was preceded by memory impairment.  It is noteworthy that  spastic paraparesis was
present in many but not all patients.  Memory impairment was present in all pa-
tients, and besides that, neuropsychological analysis showed visuoconstructional defi-
cits which were an early and prominent feature.  Psychiatric symptoms were present
in six patients, two of whom had euphoria and four depression.  In addition, some
patients showed impaired fine coordination of hands and dysarthria that suggested
cerebellar involvement.  EEG showed intermittent generalized delta-theta activity.
MRI of the head showed temporal and hippocampal atrophy, whereas PET showed
bilateral temporo-parietal hypometabolism.  In addition, variable patterns of hy-
pometabolism in PET (hemispherical asymmetry, occipital accentuation) were related
to individual deficits of cognitive performance.
Molecular genetic analysis was unexpectedly troublesome because sequencing the
exons and the immediate flanking intronic regions from genomic DNA amplified by
PCR did not disclose the mutation, which was first identified as a deletion of exon 9
through sequencing of PCR-amplified cDNA obtained from lymphoblastoid
mRNA.  By the aid of intronic primers flanking exon 9, the mutation was eventually
defined as a 4,555kb genomic deletion between exons 8 and 10.
Neuropathological analysis of five affected family members revealed an unusual
neuropathological phenotype.  The primary and association cortices and hippocam-
pus showed a profusion of eosinophilic, roundish structures with distinct borders,
termed “cotton wool” plaques (CWPs).  Predominant CWPs, a novel type of plaques,
were immunoreactive for Aβ42/43, but weakly or not at all for Aβ40 isoforms of the
amyloid β peptide (Aβ).  CWPs were devoid of a congophilic core, and only occa-
12
sional structures resembling fibrillar amyloid could be identified by electron micros-
copy.  In addition to the predominant CWPs, variable numbers of diffuse and cored
plaques were found in the cerebral cortex.
Degeneration of the lateral corticospinal tracts observed at the level of the me-
dulla oblongata and spinal cord may be correlated with spastic paraparesis.  Neu-
ropathological examination showed that CWPs were particularly numerous in the
medial motor cortex representing the lower extremities.  Most of the affected indi-
viduals showed clumsiness of the hands, dysdiadochokinesia, and  several had inten-
tion tremor.  These findings are indicators of cerebellar damage.  Diffuse and non-
neuritic cored amyloid plaques but no CWPs occurred in the cerebellum in the neu-
ropathological analysis.
CWPs were frequent in the entorhinal cortex and hippocampus; they were espe-
cially abundant in the subiculum.  The expansive CWPs displaced neurons and even
interrupted and distorted the granular cell layer of the dentate gyrus as well as the
pyramidal cell band of the hippocampus.  Confocal microscopy showed reduced den-
sity of axons within individual CWPs and few CWP-related dystrophic neurites.
The axons seemed either to wind around the CWP or to degenerate immediately
upon entering into the CWP.  It is likely that this wide disruption of cortical cytoar-
chitecture is associated with functional disturbances.
In conclusion, a novel phenotype of presenile dementia and spastic paraparesis
was identified.  Besides the clinical presentation, also the neuropathological features
were unusual.  However, the plaques were immunoreactive for Aβ, indicating that
the disease falls under the rubric of the Alzheimer syndrome.  We have designated
this clinical syndrome variant Alzheimer’s disease with spastic paraparesis (varAD).
Our observations in varAD constitute a strong argument against a simple read-
ing of the classical amyloid cascade hypothesis.  The presence of CWPs without amy-
loid cores supports the view that the extracellular, poorly soluble, congophilic amy-
loid plaques are not the only initiators of neurodegeneration in AD.  However, be-
cause the exceptionally high production of Aβ42/43 in varAD is likely to be of
pathogenetic significance, we as well as others therefore suggest that Aβ is neurotox-
ic at a stage prior to amyloid fibril formation.
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INTRODUCTION
Alzheimer’s disease is the most frequent neurodegenerative disease affecting individ-
uals of all races and ethnic backgrounds.  The first patient was reported in 1907 by
the Bavarian neuropsychiatrist and neuropathologist Alois Alzheimer.  He described
the clinical and neuropathological manifestations in a 51-year-old woman whose first
symptom was paranoid jealousy.  Her other symptoms included deficits in memory,
paranoid delusions, disorientation, and abnormal behavior.  The disease was progres-
sive and led to dementia.  At neuropathological examination, profuse senile plaques
and neurofibrillary tangles were found in the cerebral cortex (Alzheimer 1907).
Today, AD is emerging as a major health problem because prevalence of AD in-
creases with age and the proportion of elderly population is increasing, particularly
in developed societies.  Worldwide, about 20 million people suffer from AD (Haass
et De Strooper 1999).  In the United States 4 million people have Alzheimer’s dis-
ease (Evans et al. 1989).  In Finland it has been estimated that 95 000 patients will
be suffering from moderate to severe dementia by the year 2030 (Sulkava et al.
1986).  Approximately 50 to 70% of such patients are diagnosed as having Alzheim-
er’s disease according to clinical criteria (Sulkava et al. 1985, Rocca et al. 1986,
Breteler et al. 1992).  Both the prevalence and the incidence of AD double approxi-
mately every 5 years after the age of 60 (Jorm et al. 1987, Cummings et al. 1998).
The prevalence of probable Alzheimer’s disease in East Boston was 3.0% in the age-
group of those aged 65 to 74 years, 18.7% of those aged 75 to 84, and 47.2% of
those over 85 (Evans et al. 1989).  Annual incidence rates of 2.4 cases per 100,000
population between ages 40 and 60, and 127 cases per 100,000 population after age
60 have been reported (Rocca et al. 1986).
AD has an insidious onset and manifests with progressive impairment of memory
and of other higher cortical functions.  However, the diagnosis of definite AD is neu-
ropathological. Classical neuropathological hallmarks of AD include neuritic
plaques, intraneuronal neurofibrillary tangles, amyloid angiopathy, and neuronal loss
(Mirra et al. 1991,  Braak et Braak 1991, Lippa et al. 2000b).
Like many other neurodegenerative diseases, AD occurs in both familial and spo-
radic forms. Epidemiological studies indicate that approximately 30% of AD pa-
tients have at least one affected first-degree relative (Rosenberg 2000).
The majority of AD cases occur at a late age (>60 years), and show no Mendelian in-
heritance.  However, familial aggregation of Alzheimer’s disease has been recognized
since the beginning of the 20th century.  A subset of these kindreds have been iden-
tified with early-onset AD transmitted as an autosomal dominant disease with age-
dependent penetrance.  It has been estimated that autosomal dominant AD compris-
es about 5% of all AD cases (Lendon et al. 1997, Cruts et al. 1998). The allelic vari-
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ant ε4 of the apolipoprotein E gene on chromosome 19 is a well-documented risk
factor for familial and sporadic late-onset AD (Saunders et al. 1993, Kuusisto et al.
1994, Polvikoski et al. 1995), whereas α-2 macroglobulin (Blacker et al. 1998, Myl-
lykangas et al. 1999) on chromosome 12 is a likely risk factor in sporadic late-onset
AD.
Autosomal dominant AD manifests before or during the fifth and sixth decades.
It is genetically heterogeneous.  At present, three genes have been shown to be in-
volved in the etiology, the amyloid precursor protein (APP) gene on chromosome 21
(Goate et al. 1991), the presenilin 1 (PS-1) gene on chromosome 14 (Schellenberg et
al. 1992, Sherrigton et al. 1995, Clark et al. 1995), and the presenilin 2 (PS-2) gene
on chromosome 1 (Levy-Lahad et al. 1995, Rogaev et al. 1995).  Close to one hun-
dred mutations responsible for autosomal dominant AD have been identified in these
three genes, and most of these are missense mutations causing single amino acid sub-
stitutions.  However, defects in exons of these three genes are not responsible for AD
in all early-onset families (Cruts and Van Broeckhoven 1998).  It is possible that in-
tronic mutations of the APP and the presenilin genes or other thus-far unidentified
genes exist that lead to autosomal dominant AD (Lippa et al. 2000b).  The clinical
and neuropathological features of autosomal dominant AD are usually indistinguish-
able from sporadic AD (Campion et al. 1995a, Mann et al. 1992, Lippa et al. 1996).
Although autosomal dominant AD is rare, it has proven to be of crucial scientific
value in elucidating the molecular pathogenesis of AD.
The subject of this thesis is to describe a novel inherited variant of Alzheimer’s
disease identified in a Finnish family.  This new variant Alzheimer’s disease (varAD)
is associated with a distinctive clinical and neuropathological phenotype caused by
an unusual genomic deletion mutation encompassing exon 9 of the presenilin 1 (PS-
1) gene and parts of the flanking introns.  The pathogenesis of varAD will provide
new insights of wider interest in regards to AD in general.
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REVIEW OF THE LITERATURE
1.  SPORADIC ALZHEIMER’S DISEASE
1.1.  Clinical features of sporadic AD
1.1.1.  Symptoms and signs
The illness remains subclinical for years, and the onset of AD is typically insidious,
making it difficult to specify the exact time of onset.  Furthermore, gradual progres-
sion of symptoms is typical.  At the late stage, patients become mute, uncompre-
hending, and bedridden (Morris 1996).  Duration from onset of the disease to death
is on average from 8 to 10 years (Walsh et al. 1990).  According to the report of a
Work Group on the Diagnosis of Alzheimer’s Disease established by the National In-
stitute of Neurological and Communicative Disorders and Stroke (NINCDS) and the
Alzheimer’s Disease and Related Disorders Association (ADRDA), the diagnosis of
possible and probable AD is clinical (McKhann et al. 1984).  Previous exclusion of
other diseases causing cognitive impairment such as delirium, depression, or hy-
pothyreosis is needed before establishment of the diagnosis of AD.
The evaluation of a patient with cognitive decline begins by patient and inform-
ant history.  The salient cognitive feature of AD is memory impairment and most
commonly it is also the presenting symptom (Morris 1996).  Typical symptoms in-
clude difficulty recalling names of individuals, telephone numbers, and details of
events of the day.  In addition, repetitive comments are typical.  After the history, is
a cognitive evaluation often by the Mini-mental state (MMS) test (Folstein et al.
1975).  At the early stage, the patient has problems in short-term memory, in verbal
and nonverbal recognition memory, and a deficit in acquisition of novel information,
whereas remote memory is relatively spared.  In addition, in the initial mild stage of
AD manifests characteristically in difficulty recalling details of recent events or con-
versations, minor temporal and geographic disorientation, difficulties with calcula-
tion, and reduced insight and initiative (Morris 1996).  Apraxia or incapacity to per-
form motor tasks unexplained by a primary motor disturbance is present in up to
one-third of patients of the early stage of AD and in an increasing proportion in later
stages (Della Sala et al. 1987, Cummings and Benson 1992).
However, social skills, basic self-care abilities, emotional life and responses are
generally well-preserved at the early stage of the disease.  Clinical examination is
completed by medical and neurologic examination.  Besides memory and visuospatial
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disturbances, extrapyramidal signs such as rigidity, bradykinesia, shuffling gait, and
postural change are relatively common in AD but, in contrast, primary motor func-
tion and cerebellar function are spared (Cummings et al. 1985, Funkenstein et al.
1993).
At the moderate stage of AD, memory of recent events is lost and only highly
learned material is recalled.  Furthermore, language dysfunction is common, and of-
ten both language comprehension and output are compromised (Morris 1996).  The
language disorder resembles but is not identical to transcortical sensory aphasia, and
as the disease progresses, the language disorder resembles Wernicke’s aphasia (Cum-
mings et al. 1985).  Behavioral disturbances such as aggression and delusions often
complicate the moderate stage of AD, and supervision for daily self-care functions is
needed.
At the late stage of AD, self-care becomes impossible as patients lose their inde-
pendence in daily activities, and most patients are institutionalized.
1.1.2.  Neuropsychology
In the clinical and preclinical diagnosis of AD, neuropsychological assessment is an
important tool (Petersen et al. 1994, Linn et al. 1995, Jacobs et al. 1995, Almkvist
et al. 1996a, Almkvist et al. 1996b, Diaz-Olavarrieta et al. 1997).  In addition, it
can be used in follow-up studies of disease progression and clinical trials.  However,
the most significant aim of neuropsychological evaluation is to gain facts with re-
spect to the presence, magnitude, and nature of cognitive compromise.  Memory im-
pairment is the first sign of incipient disease and the most prominent, central, and
consistently observed deficit in all types of AD.  Importantly, a preclinical stage of
detectable cognitive deficits can precede the clinical diagnosis of probable AD by
many years (Linn et al. 1995).  On the other hand, in different stages of AD, neu-
ropsychological findings are variable.
Measures of verbal learning and memory and of immediate auditory attention
span are among the most sensitive instruments to detect early changes in cognitive
functioning (Linn et al. 1995).  Already at a very early stage of AD, acquisition and
use of semantic cues are disturbed (Petersen et al. 1994).  Other neuropsychological
symptoms such as impairments in language, praxis, calculation, and behavioral Aβ-
normalities show more diversity.
1.1.3.  Neurophysiology
The importance of electroencephalography (EEG) as a routine method of diagnosing
AD has diminished, while neuroimaging has become more accurate.  At the early
stage of AD, EEG may remain normal.  Furthermore, during a one-year follow-up,
50% of AD patients have shown normal EEG recordings with no deterioration
(Soininen et al. 1989).  At more advanced stages of AD most patients have abnormal
EEG.  These EEG changes include diffuse slowing of the alpha rhythm and appear-
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ance of theta and delta activity (Penttilä et al. 1985, Helkala et al. 1991).
1.1.4.  Neuroimaging
Brain imaging by computed tomography (CT) or magnetic resonance (MRI) is gener-
ally used in the clinical diagnosis of dementia for two reasons: First, to exclude other
illnesses that are potentially amenable to treatment, and second, to seek evidence as
to an imaging procedure that may offer some specific additional diagnostic informa-
tion such as medial temporal- or focal atrophy and vascular changes (Scheltens 2001).
Although generalized brain atrophy can be detected by CT, in AD, it is of very limit-
ed diagnostic value.
MRI has higher sensitivity and can be focused on those areas that are affected ear-
liest.  Atrophy of the medial temporal lobes, especially atrophy of the entorhinal cor-
tex and of the hippocampi and perihippocampal areas are characteristic in AD (Mori
et al. 1997, Laakso et al. 1995, Juottonen et al. 1999).
In AD patients, PET has demonstrated bilateral reduction in regional cerebral
blood flow (rCBF) and diminished oxygen utilization in temporoparietal and medial
temporal cerebral cortices (Frackowiak et al. 1981, Kumar et al. 1991, Ishii et al.
1996, Ishii et al. 1997).  The decreasing regional cerebral metabolic rate for glucose
(rCMRglc) involves the parietal and temporal lobes that is already detectable in the
very early stage of AD (Julin et al. 1998).  Although it is not a typical PET feature,
some AD patients show metabolic asymmetry (Friedland et al. 1985).  Interestingly,
the site of this asymmetry often correlates with clinical manifestation.  Patients with
greater left hemisphere hypometabolism tend to demonstrate language disorders,
whereas patients with greater right hemisphere hypometabolism show more promi-
nent visuospatial disturbances (Haxby et al. 1988, Koss et al. 1985).
1.2.  Main neuropathological features
The diagnosis of definite AD requires histopathologic confirmation.  Of 106 autop-
sied patients with a clinical diagnosis of probable AD, 87% had AD according to the
CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) neuropatho-
logical criteria (Gearing et al. 1995).
End-stages of AD are easily recognized at neuropathological examination.  In
contrast, evaluation of cases with mild to moderate affection is more difficult (Braak
et  Braak 1991).  AD is characterized by reduction in brain volume and weight and
ventricular enlargement (Esiri et al. 1997).  Histological hallmarks of  AD brains are
β-amyloid plaques, intraneuronal neurofibrillary tangles, and neuronal degeneration
and loss, preceded by loss of synaptic density (Lippa et al. 2000b).
1.2.1. Plaques
Senile plaques are lesions composed of diverse amyloid peptides and associated mole-
cules, degenerating neuronal processes, and reactive glia.  In general, an essential
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component of senile plaques in AD is the β amyloid peptide (Aβ), a 4 kDa protein
derived from the amyloid precursor protein (APP).  Patients with AD usually show
several types of plaques; the term “senile plaque” is used to cover a number of their
different subtypes.
Senile plaques are stained by different methods.  In general, they are difficult to
see in sections stained with hematoxylin or cresyl violet but are easily demonstrated
the silver impregnation method described by Bielschowsky or the methenamine sil-
ver technique.  Congo red PAS, or thioflavin S, in particular, are the best techniques
for demonstrating the amyloid component.
Several classifications of plaques have been published.  However, a recent author-
itative article lists three main types of plaques (Dickson 1997):  Plaques with exten-
sive or poorly circumscribed Aβ deposits are categorized as “diffuse plaques”.  These
are composed of amorphous aggregates of Aβ protein and contain at most, only a few
amyloid fibrils.  They lack dense amyloid cores and are devoid of pathological neur-
ites.  Diffuse plaques in the cerebellar molecular layer and striatum may be associated
with ubiquitin-immunoreactive dystrophic neurites.  However, diffuse plaques are
not identifiable in sections stained by hematoxylin-eosin but can be visualized by
methenamin silver staining and are immunoreactive for Aβ peptide.
Plaques with prominent neuritic elements are referred to as “neuritic plaques”.
The typical neuritic plaque is a spherical structure 50 to 200 µm in diameter, con-
sisting of a central immunoreactive amyloid core surrounded by dystrophic neurites
(Cummings et al. 1998).  These neurites are heterogeneous.  Some neurites are of
dystrophic type and contain degenerating synaptic elements with accumulation of
membranous material and lysosomal dense bodies, while others are PHF-type neur-
ites containing paired helical filaments (Dickson 1997).  PHF-type neuritic degener-
ation correlates well with cognitive dysfunction (Dickson 1997).  Dystrophic neur-
ites are the major type seen in aged human brains that can be detected by different
staining methods.  Methods exits to detect lysosomal enzyme activity (acid phos-
phatase) or molecules (cathepsin) that readily stain dystrophic neurites, while other
markers used in detecting dystrophic neurites recognize specific glycosyl groups
(concanavalin A) or components of the degenerating synaptic terminals (antibodies to
chromogranin A).  In addition, antibodies to ubiquitin can detect dystrophic neur-
ites (Dickson 1997).
Plaques composed exclusively of amyloid are classified as “amyloid plaques”
(Dickson 1997). At an early stage of AD, plaques are found in isolated areas of the
association cortex of the frontal and anterior temporal lobes and in the amygdala, the
entorhinal cortex, and the hippocampus. Neuritic plaques tend to occur in deeper
layers of the cortex, whereas diffuse plaques being predominant in the more superfi-
cial layers (Esiri et al. 1997).
In addition to the three main types of plaques, a fourth type has been described
in the hippocampal region of AD patients and in individuals of advanced age.  This
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type has been called “plaque A” (Probst et al. 1991).  This non-congophilic (pre-
amyloid) plaque A is spherical in shape and 100-200 µm in diameter, with sharply
outlined borders.  Its main feature is a single centrally located cell, which stains with
RCA-1 lectin and can therefore be considered a microglial cell (Probst et al. 1991).
1.2.2.  Neurofibrillary changes
AD is associated with severe cytoskeletal alterations of various kinds of lesions,
namely neuritic plaques and neurofibrillary tangles, and neurophil threads (Braak
and Braak 1991).  Neuritic plaques are marked by a dense feltwork of argyrophilic
nerve cell processes,  neurofibrillary tangles are composed of bundles of paired helical
filaments containing the microtubule-associated protein tau.  These neurofibrillary
tangles are present intraneuronally in AD and are composed predominantly of hyper-
phosphorylated tau.  They develop within the nerve cell soma from whence they may
extend into the dendrites, while the proximal axon remains free of  any (Braak and
Braak 1991).  Neurofibrillary tangles also occur in non-AD diseases and therefore are
less specific to AD than neuritic plaques (Cummings et al. 1998).  Neurofibrillary
tangles consist of argyrophilic processes of nerve cells loosely scattered throughout
the neurophil, and in the isocortex they are localized in dendrites of tangle-bearing
pyramidal cells (Braak and Braak 1991).
1.2.3.  Amyloid angiopathy
In AD, Aβ deposits not only in the cerebral parenchyma of the amygdala, hippocam-
pus, and neocortex, but also in the walls of leptomeningeal and intracortical blood
vessels, resulting in amyloid angiopathy.  Vascular amyloid stains with Congo red.
The amyloid in cerebral blood vessels most commonly consists of  Aβ1-40 (Prelli et
al. 1988) and is usually deposited in the walls of small arteries and arterioles.  Amy-
loid angiopathy is associated with increased risk for intracerebral hemorrhage (Gil-
bert et al. 1983).
1.3.  Genetic risk factors for Alzheimer’s disease
1.3.1.  Apolipoprotein E
Genetic linkage studies in pedigrees with predominantly late-onset familially aggre-
gated AD have provided evidence for AD susceptibility locus which maps to chro-
mosome 19q12-q13 (Pericak-Vance et al. 1991).
Two years later it was shown that the ApoE ε4-allele is a significant genetic risk
factor not only in familial (Strittmatter et al. 1993) but also in sporadic late-onset
AD (Saunders et al. 1993).  Apolipoprotein E (ApoE) is a glycoprotein of approxi-
mately 34 kDa which plays a critical role in lipid transport, homeostasis, and catabo-
lism (Mahley 1988, Davignon et al. 1988).  At the single ApoE locus there are three
alleles: ε2, ε3, and ε4, corresponding to six phenotypes (Rall et al. 1982, Mahley
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1988).  Elevated risk for late-onset AD among individuals with the ε4-allele has
been confirmed in many studies (Poirier et al. 1993, Saunders et al. 1993, Kuusisto
et al. 1994, Farrer et al. 1997).  Meta-analysis of 40 studies representing nearly 30
000 ApoE alleles demonstrated that the ε4-allele is a major risk factor for sporadic
AD in Caucasians, African-Americans, Hispanics, and Japanese, and in both men and
women (Farrer et al. 1997).  Caucasian individuals with the ε2/ε4, ε3/ε4, and ε4/ε4
genotypes have an increased risk for late-onset AD (Farrer et al. 1997, Evans et al.
1997).  In addition, a dose-dependent relationship exists between the number of cop-
ies of ε4, and the age of onset of AD so that subjects with ε4/ε4 genotype have an
earlier onset than do heterozygous ε4 subjects and have a higher plaque burden than
do subjects with no ε4 alleles (Corder et al. 1993, Strittmatter et al. 1993, Polviko-
ski et al. 1995).  It has been suggested that the effect of the ApoE ε4 allele on the
risk of AD is age-dependent, and is no longer present in very old age (Blacker et al.
1997, Juva et al. 2000), but recent studies show that the ApoE ε4 effect is evident at
all ages between 40 and 90 years (Farrer et al. 1997, Polvikoski et al. 2001).
The ApoE ε2 allele appears to be protective, both by lowering risk for AD and
increasing the age of onset (Saunders 2000).  Consequently, the risk decreases for
people with genotypes ε2/ε2 and ε2/ε3, and the ε2/ε3 genotype appears equally pro-
tective across different ethnic groups (Farrer et al. 1997).
The mechanisms of ApoE in relation to AD are insufficiently understood.  ApoE
plays a significant role in the peripheral and central nervous system in regeneration
after injury as well as in normal brain lipid metabolism (Strittmatter et al. 1993).
On the other hand, ε4 shows increased affinity for Aβ and is found in senile plaques
in AD, thus acting as a pathological chaperone (Strittmatter et al. 1993).  Although
inheritance of the ApoE ε4 allele confers increased risk for AD, it is neither sufficient
nor necessary to cause the disease.
1.3.2.  Others
Late-onset AD is the most common form of the disease, but 30 to 40% of patients
with late-onset sporadic AD do not carry the ApoE ε4 allele (Roses 1995).  For these
reasons, the search for new genetic risk factors in different ethnic groups has been
vigorous.  Statistical evidence has been presented for a susceptibility locus on chro-
mosome 12 in a complete genome screen in familial AD (FAD) (Pericak-Vance et al.
1997).  In addition, other evidence is suggestive of linkage to an overlapping region
on chromosome 12 (Rogaeva et al. 1998).  Alpha-2-macroglobulin (A2M), encoded
by the A2M gene on chromosome 12, has been reported to bind tightly to the β-
amyloid protein which is the major component of amyloid plaques (Du et al. 1997).
Furthermore, A2M is a serum pan-protease inhibitor implicated in AD, based on its
ability to mediate the clearance and degradation of Aβ (Blacker et al. 1998).  Previ-
ous studies have suggested an association between the alpha-2 macroglobulin and
late onset-Alzheimer’s disease (Blacker et al. 1998, Myllykangas et al. 1999).  How-
ever, several other studies show controversial results (Wu et al. 1998, Gibson et al.
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2000, Sodeyama et al. 2000, ).  In addition, linkage studies have suggested that ge-
netic risk factors for late-onset AD may be located on chromosomes 3, 5, and  partic-
ularly on chromosome 10 (Tanzi 1996,  Kehoe et al. 1999, Bertram et al. 2000, Mye-
rs et al. 2000, Ertekin-Taner et al. 2000).  Several other risk genes for AD have been
suggested but not constantly confirmed.
2.  AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE
2.1.  Genetics
The majority of AD cases occur at a late age and do not show Mendelian inheritance.
However, epidemiological studies indicate that approximately 25 to 40% of AD pa-
tients have at least one affected first-degree relative (Van Broeckhoven et al. 1995,
Rosenberg 2000).  A subset of these kindreds have been identified with early-onset
AD transmitted as an autosomal dominant trait with age-dependent penetrance.
Autosomal dominant AD manifests before or during the fifth and sixth decade
and comprises about 5 to 10% of all AD cases (Lendon et al. 1997, Cruts et al.
1998).  It is genetically heterogeneous.
At present, three genes have been shown to be involved in AD etiology: the
amyloid precursor protein (APP) gene on chromosome 21 (Goate et al. 1991), the
presenilin 1 (PS-1) gene on chromosome 14 (Schellenberg et al. 1992, Sherrigton et
al. 1995, Clark et al. 1995) and the presenilin 2 (PS-2) gene on chromosome 1 (Levy-
Lahad et al. 1995, Rogaev et al. 1995).  In these three genes have been identified
about 100 mutations responsible for autosomal dominant AD.  However, defects in
these three genes are not responsible for AD in all early-onset families (Cruts and
Van Broeckhoven 1998).  Autosomal dominant AD is rare but has proven to be of
important scientific value in elucidating the molecular pathogenesis of AD.
2.1.1.  Amyloid precursor protein (APP) gene mutations
APP gene was the first gene to be identified in association with inherited suscepti-
bility to AD, and the first point mutation of the APP gene was found at codon 717
(Goate et al. 1991).  This discovery was preceded by the observation that Down syn-
drome (trisomy 21) is associated with augmented deposition of Aβ, and virtually all
individuals with Down syndrome who live to the age of 40 develop the histopatho-
logical manifestation of AD (Mann and Esiri 1989).  The early neuropathological
changes are apparently due to increased gene dosage and overproduction of β-amy-
loid, which as in other APP mutations is a likely underlying mechanism of the AD
histopathology in Down syndrome (Lannfelt et al. 1994).
APP is a type I, integral membrane glycoprotein encoded by a gene on chromo-
some 21q21.2.  (Yu et al. 1992) The APP protein undergoes a series of endoproteo-
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lytic cleavages and is metabolized via one of at least three pathways.  One of these oc-
curs in part in the endosomal-lysosomal compartment and involves the putative β-
and δ-secretases which give rise to a series of peptides containing the 40-42 amino
acid Aβ peptide.  Furthermore, Aβ42 and Aβ43 are thought to be more fibrillogenic
and more neurotoxic than the Aβ40, that is the predominant isoform produced dur-
ing the normal metabolism of APP (Yankner et al. 1990).
Although the normal function of APP is unknown, mutations have been shown
to alter endoproteolysis of APP such that more of the Aβ42 form is produced (Hardy
1997, Citron et al. 1992).  In addition, FAD mutations in APP may also alter the in-
tracellular trafficking and overall maturation or processing of APP (Tanzi et al.
1996).
In general, mutations of APP gene are rare.  Molecular genetic studies have
shown that APP mutations are responsible for only approximately 5% to 7% of
early-onset FAD (Van Broeckhoven 1995, Tanzi et al. 1996).  At present, at least
seven mutations at eight codons of the APP gene have been identified in over 20
families (Goate et al. 1991, Hendricks et al. 1992, Mullan et al. 1992, Tanzi et al.
1996, Cruts and Van Broeckhoven 1998).
These mutations have been shown to be nearly 100% penetrant (Tanzi et al.
1996).  The mutations are clustered within and around the amyloidogenic region
(Tanzi et al. 1996, Cruts and Van Broeckhoven 1998).  Mutations at codon 717 are
present in several families from different ethnic groups, but the mutations at codon
692 and 670/671 are rare (Goate et al. 1991, Karlinsky et al. 1992, Mullan et al.
1992, Hendricks et al. 1992).  A double mutation in APP at codons 670/671 has
been shown to cosegregate with the disease in two large Swedish pedigrees (Mullan
et al. 1992, Lannfelt et al. 1994, Almkvist et al. 1995).  Mutations in codons 692
and 693 of the APP gene lead to presenile dementia and cerebral hemorrhages (Levy
et al. 1990, Van Broeckhoven et al. 1990, Hendricks et al. 1992).  Patients with he-
reditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D) have
a mutation in codon 693 in exon 16 of the APP gene resulting in a glutamate-to-
glutamine substitution (Levy et al. 1990).  HCHWA-D is associated with a deposi-
tion of Aβ in cerebral blood vessels causing recurrent cerebral hemorrhages.  A muta-
tion in which alanine is substituted for the glycine of the neighboring codon 692
causes presenile dementia and cerebral hemorrhage (Hendriks et al. 1992).
2.1.2. Presenilin 1 (PS-1) gene mutations
After the discovery that APP mutations were a rare cause of early onset FAD, molec-
ular genetic linkage studies indicated a locus on chromosome 14 (Schellenberg et al.
1992).  Soon it was shown that the presenilin-1 (PS-1) gene located on chromosome
14q24.3 is the major gene responsible for early-onset autosomal dominant forms of
FAD (Sherrington et al. 1995, Clark et al. 1995, Campion et al. 1995a, Poorkaj et al.
1998).
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The PS-1 gene encodes a 467 amino acid membrane serpentine protein with
eight transmembrane domains and two hydrophilic acidic domains, one at the N-ter-
minus (Hutton et al. 1997, De Strooper et al. 1998, Haass et De Strooper 1999).
Presenilins are expressed in neurons throughout the central nervous system and also
in other organs and are localized in intracellular membranes and mainly in endoplas-
mic reticulum (De Strooper et al. 1998).  Immunoblotting studies suggest that  the
PS-1 protein is about 50 kDa in size (De Strooper et al. 1997).  At genomic level this
gene comprises 12 exons spanning approximately 75 kb, with the open reading
frame limited to exons 3 to12 and spanning approximately 24 kb (Clark et al. 1995,
Tanzi et al. 1996).  Approximately 75% of known PS-1 mutations occur in exons 5,
7, and 8 (Smith et al. 1999).  Most PS-1 gene mutations are missense mutations
caused by a single amino-acid substitution.  In 1995 a different kind of mutation
was reported (Perez-Tur et al. 1995).  This mutation in a British kindred involves a
point mutation in the splice acceptor site at the 5’ end of exon 10 (Perez-Tur et al.
1995).  Two years later, deletion of exon 9 of the PS-1 gene was identified in an Aus-
tralian family with dementia and spastic paraparesis (Kwok et al. 1997).  The third
splicing defect mutation was reported in a Japanese kindred (Sato et al. 1998).
Estimates of the proportion of early-onset FAD due to mutations in the PS-1
gene vary from 18% to 70% (Campion et al. 1995b, Hutton et al. 1997, Cruts et al.
1998).  To date, over 60 mutations of PS-1 have been discovered, and have been
identified all over the world in more than 80 families of different ethnic origins
(Tanzi et al. 1996, Cruts et al. 1998, Rosenberg 2000 ).
Mutations in the PS-1 gene result in the most severe form of the disease with au-
tosomal dominant inheritance, complete penetrance, and onset occurring as early as
30 years of age (Poorkaj et al. 1998).  The range of onset for PS-1 gene mutations is
between 30 to 65 years (Campion et al. 1996, Lendon et al. 1997, Kwok et al. 1997,
Poorkaj et al.1998, Rosenberg 2000).  The onset is earlier and the disease duration
shorter than in sporadic patients or patients with  the APP gene mutation (V717I)
(Lippa et al. 1996, Russo et al. 2000).
2.1.3.  Presenilin 2 (PS-2) gene mutations
Soon after the discovery of the PS-1 gene underlying AD, a homologous gene called
the PS-2 gene was identified on chromosome 1q31-q42 (Levy-Lahad et al. 1995, Ro-
gaev et al. 1995).  The amino acid sequence identity between PS-1 and PS-2 proteins
is approximately 67% (Tanzi et al. 1996).  However, the pattern of expression of the
PS-2 gene is somewhat different from that of PS-1.  PS-2 is expressed maximally in
cardiac muscle, skeletal muscle, and the pancreas but less homogeneously in the
brain and in the peripheral tissues (Rogaev et al. 1995).  In comparing the frequency
of PS-1 gene mutations with PS-2 gene mutations in a large set of patients, it was
obvious that mutations of the PS-2 gene are rare (Sherrington et al. 1996). At
present, only three missense mutations have been identified (Levy-Lahad et al. 1995,
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Rogaev et al. 1995, Cruts et al. 1998).  The first mutation (N141I) was detected in
patients of families  of Volga German ancestry (Levy-Lahad et al. 1995) and the sec-
ond mutation (M239V) in an Italian family (Rogaev et al. 1995), while the third
(R62H) was observed in a sporadic Dutch AD case with an onset of 62 years (Cruts
et al. 1998).
It is however, possible that PS-2 families have been overlooked because of the
wide variation in age of onset and because of incomplete penetrance of the PS-2 gene
mutations (Cruts et al. 1998).  In general, the age of onset of AD in individuals with
PS-2 gene mutations is higher than in individuals with PS-1 mutations, the age-
range being between 40 and 88 years (Lendon et al. 1997, Sherrington et al. 1996).
The underlying mechanism for this variation is unsolved.  In addition, death occurs
later in the PS-2 AD group than in the PS-1 or APP AD groups (Lippa et al. 2000b).
In contrast to PS-1 and APP gene mutations, there is at least one instance of non-
penetrance in an asymptomatic individual over 80 years whose offspring was affected
(Bird et el. 1989).
2.1.4.  Autosomal dominant Alzheimer’s disease and ApoE
Previous studies suggest that the age of onset of FAD is modulated by the ApoE gen-
otype (Blacker et al. 1996).  Consequently, carriers of the APP (V717I) mutation
having one or more ε4 alleles at ApoE have an earlier onset of the disease than do car-
riers who have  no ε4 alleles of ApoE (St George-Hyslop et al. 1994).
However, the relationship between presenilin mutations and apolipoprotein E
has remained to some extent controversial.  Most studies show that ApoE does not
modulate the age of onset in families with a mutation in the PS-1 gene (Van Broeck-
hoven et al. 1994, Kwok et al. 1997).  Furthermore, evidence exists that the ApoE
genotype does not influence neuropathologic features in patients with FAD with
linkage to chromosome 14 or in patients with FAD with linkage to chromosome 21
(Lippa et al. 1996).  These observations suggest the existence of other genetic and en-
vironmental factors modifying the AD phenotype in PS-1 families.
2.2.  Clinical features
In contrast to the marked genetic heterogeneity, distinctive clinical features are rare-
ly reported in FAD.  Before molecular genetic studies were available, the main fea-
tures of FAD were suggested to be earlier age of onset with more rapid course, great-
er prevalence of language disturbances, seizures, myoclonic jerks, and shorter survival
than in sporadic AD (Bird et al. 1989, Kennedy et al. 1995, Swearer et al. 1996).
Nowadays, specific mutations can be related to characteristic clinical features.
Most reported patients with PS-1 mutations have onset of symptoms before age
50 years (Van Broeckhoven 1995), while the age-range for PS-2 gene mutations is
between 40 and 88 (Lendon et al. 1997).  Early progressive aphasia, myoclonus, gen-
eralized seizures, and paratonia are apparently more common in PS-1-encoded FAD
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than in patients with APP (codon 717) mutations (Lampe et al. 1994).
Those affected persons with the PS-2 gene mutation in the Volga German
kindreds are reported to have generalized seizures, rigidity, tremor, myoclonus, and
language deficits (Bird et al. 1989).
In addition, a few reports describe phenotypic heterogeneity between different
mutations of the same gene.  Mutations of the APP gene that lie on either end of the
β-peptide (Aβ) sequence cause a typical presenile FAD.  However, a mutation of co-
don 693 of the APP gene within the Aβ sequence causes hereditary cerebral hemor-
rhage of the Dutch type (Levy et al. 1990), whereas a mutation of codon 692 leads to
presenile dementia and cerebral hemorrhage (Hendriks et al. 1992).
Mutations of the PS-1 are the most common of autosomal dominant FAD, and
the majority of over 60 mutations are associated with typical clinical features of AD.
However, there are a few exceptions: headache is a distinctive symptom in FAD, due
to the E280A mutation of the PS-1 gene (Lopera et al. 1997); early and prominent
myoclonus mimicking Creutzfeldt-Jakob disease is associated with the M146V mu-
tation of the same gene (Haltia et al. 1994, Clark et al. 1995).
2.3.  Neuropsychological features
Kindreds with specific mutations provide an opportunity to study neuropsychologi-
cal features related to certain mutations.  However, surprisingly few studies with a
limited number of patients provide neuropsychological data on FAD in association
with specific mutations.
Patients with a  missense substitution of isoleucine for valine at codon 717 of the
APP gene show early neuropsychological manifestations such as deficits in memory,
in cognitive processing speed, and in attention to complex cognitive sets (Karlinsky
et al. 1992).  Substitution of phenylalanine for valine at codon 717 of the APP gene
is associated with a neuropsychological profile in which recent memory, information-
processing speed, sequential tracking, and conceptual reasoning are the earliest cog-
nitive functions affected.  However, at least early in the course of the disease, lan-
guage and visuoperceptual skills are largely spared (Farlow et al. 1994).
In general, APP mutations are associated with disturbance in attention and with
psychiatric symptoms (Matsumura et al. 1996, Almkvist et al. 1995), while language
functions are usually preserved.
PS-1 mutations are more often associated with language impairment (Campion
et al. 1995a, Kennedy et al. 1995, Fox et al. 1997, Roselli et al. 2000).  Chromo-
some 14- linked FAD was initially associated with a neuropsychological profile char-
acterized by early memory deficit with early dyscalculia and an impairment in speech
production.  Later this mutation was established as a point mutation M139V in the
presenilin 1 gene (Kennedy et al. 1995, Fox et al. 1997).  Further neuropsychological
evaluation disclosed a sequence of deficits with early memory loss initially selective
for verbal memory in some individuals, followed by loss of arithmetic skills, whereas
naming and object-perception skills were relatively preserved.  A speech production
deficit characterized by stammering was seen in all surviving affected members of a
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British family (Fox et al. 1997).
2.4.  Neuropathological features
Apart from the more intense pathology, more numerous lesions, and a faster disease
process, neuropathological findings in FAD overlap with and are similar to those of
sporadic AD (Lippa et al. 1996, Lippa et al. 2000a).
 Actually, it is surprising that mutations of different genes of chromosomes 1,
14, and 21 produce exactly the same neuropathological phenotype.  It is possible
that slight pathological differences may not have been recognized in earlier studies.
However, careful study of neuropathological features of FAD sometimes shows subtle
differences in features among AD groups.
Mutations at codon 717 of the APP gene result in classic but severe neuropatho-
logical features typical of AD without unusual characteristics (Mann et al. 1992,
Karlinsky et al. 1992).  However, two mutations of the APP gene cause more exten-
sive angiopathy than that seen in sporadic AD.  A mutation at codon 693 of the APP
gene, causing E693Q substitution, leads to hereditary cerebral hemorrhage with
amyloidosis of the Dutch type (HCHWA-D) without mature neuritic plaques (Levy
et al. 1990).  A mutation at the neighboring codon 692 causing A692G substitution
leads to HCHWA of the Flemish type (Hendriks et al. 1992).  Patients with
HCHWA of the Flemish type also develop dementia, and their neuropathology
shows senile plaques with large Aβ cores surrounded by a meshwork of dystrophic
neurites (Cras et al. 1998).
FAD associated with the PS-1 gene mutations is, in general, pathologically indis-
tinguishable from sporadic AD, apart from exceptionally florid amyloid and neurofi-
brillary pathology (Lippa et al. 1996, Campion et al. 1995a, Fox et al. 1997, Smith
et al. 1999).  However, careful analysis reveals that there is scarce pathological diver-
sity caused by PS-1 gene mutations.  Neuropathological analysis of patients with the
M146V mutation of the PS-1 gene showed mild vacuolar changes resembling spong-
iform changes seen in Creutzfeldt-Jakob disease (CJD).  In contrast to CJD, these
vacuolar changes were restricted to the medial temporal cortex and amygdala (Haltia
et al. 1994).  Furthermore, in a kindred with the E280A mutation, the entire cere-
bral cortex showed prominent vacuolation of neurophils in superficial layers, accom-
panied by the severe gliosis often seen in CJD (Lopera et al. 1997).  Mutation A260V
was associated with discrete silver- and ubiquitin-positive inclusions resembling Pick
bodies in the neurons of the dentate gyrus (Ikeda et al. 1996).  Histopathology of
L250S FAD showed a large number of senile and diffuse plaques in the cerebellum.
This mutation was associated with large numbers of small, diffuse “cloud-like”
plaques in the region of the nucleus basalis of Meynert.  There was a selective distri-
bution of these plaques and neurofibrillary tangles in the deep gray nuclei.  The
putamen contained many senile plaques which contrasted with a paucity of senile
plaques in the globus pallidus.  Neurofibrillary tangles were plentiful in the midline
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nuclei of the thalamus, but were scarce in the dorsomedial nucleus (Harvey et
al.1998).
Very few reports concern neuropathology associated with PS-2 mutations, proba-
bly because of the rarity of  mutations in this gene.  Neuropathological analysis of
patients with a PS-2 gene mutation in the Volga German kindred showed typical
AD changes with amyloid angiopathy, but, surprisingly, there were neuritic plaques
in the cerebellum (Bird et al. 1989).
3.  HYPOTHESES FOR THE PATHOGENESIS OF ALZHEIMER’S
DISEASE
3.1.  Amyloid cascade hypothesis
The amyloid cascade hypothesis of AD is based on the idea that the primary cause of
the  neurodegenerative process in AD is abnormal generation or deposition of Aβ, ei-
ther by direct neurotoxic effect or by the induction of associated toxic factors (Hardy
et Higgins 1992).  Aβ is derived from amyloid precursor protein (APP), a complex
transmembrane protein with several different isoforms, which in its longest isoform
is a single transmembrane-spanning polypeptide of about 700 amino acids (Hardy et
Duff 1993, Tanzi et al. 1996).  APP is processed by several alternative metabolic
pathways.  The major pathways are endosomal-lysosomal and secretory.  Three en-
zymes: α-, β-, and γ-secretase, cleave APP into Aβ fragments of different sizes.  The
secretory pathway (α-route) for APP begins with cleavage by an α-secretase which
cuts within the Aβ domain between residues 16 and 17.  This cleavage produces a
carboxy terminal fragment (C-100) which is considered to be irrelevant to amyloido-
sis because it lacks the first 16 amino acid residues of Aβ.  However, Aβ in AD is de-
rived from APP metabolism via the endosomal-lysosomal pathway.  This pathway in-
volves the putative β- and γ-secretases which give rise to a series of peptides contain-
ing the 40-42 amino acid Aβ peptide.  AD brains have demonstrated the major Aβ
peptides to be Aβ 1-40 and Aβ 1-42, Aβ42 and Aβ43 are considered particularly fi-
brillogenic and neurotoxic (Yankner et al. 1990). This endosomal-lysosomal pathway
(β-route) results in the cleavage event of the liberation of Aβ.  In the first phase of
the β-route, β-secretase cleaves the APP molecule at the amino terminus of Aβ.
Then a γ-secretase cleaves the molecule at the carboxy terminus, releasing the Aβ
fragment, of which approximately one-fifth is in 42-amino-acid form (Cummings et
al. 1998, Hardy et Higgins 1992).  However, it is unclear whether Aβ has direct
neurotoxity or if neurotoxity is due to induction of a secondary mechanism such as
inflammatory changes (Tanzi  et  al. 1996, Selkoe 1997).  The gradual cerebral build-
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up of Aβ first in soluble and then in particulate form, especially in plaques, appears
to result in inflammatory changes.  This in turn results in local microglial and astro-
cytic activation, with concomitant release of cytokines and acute-phase proteins (Mc-
Geer et al. 1994, Selkoe 1997).  Secondly, it has been suggested that filamentous Aβ
alters the glia and neurons by causing changes in calcium homeostasis as well as
causing oxidative injury by free radical formation (Selkoe 1997, Behl et al. 1994,
Cummings 1998).
3.2.  Other hypotheses
Neurofibrillary tangles, which contain paired helical filaments (PHFs) and straight
filaments, are characteristic of AD pathology.  PHFs are formed primarily from ab-
normal aggregation of tau proteins.  The second most important theory of AD em-
phasizes the view that abnormal phosphorylation of tau proteins play an important
role in the pathophysiology of AD (Grundke-Iqbal et al. 1986) possibly because of
impaired intracellular transport.  However, it has been shown that specific mutation
of the tau gene on chromosome 17q21-22 is causal for frontotemporal dementia and
not for AD (Hutton et al. 1998, Baker et al. 2000).  In addition, other hypothesis of
AD pathophysiology include theories of an autoimmune etiology, inflammatory
processes, and oxidative stress (Cummings et al. 1998).
3.3. Function and dysfunction of the presenilins
The actual biological roles of PS proteins or the mechanisms by which they cause
FAD are not fully understood.  However, mutant presenilins interfere with the nor-
mal processing of APP.  Mutations in the PS-1 gene, PS-2 gene, and APP genes have
been shown to alter APP processing so that more of the peptide Aβ42 or Aβ43 is
produced (Haass et DeStrooper 1999).  Long-tailed Aβ is thought to be more neuro-
toxic and fibrillogenic than the Aβ ending at residue 40, which is the most common
isoform produced during normal metabolism of APP (Yankner et al. 1990).
Because presenilins are required for the γ-secretase activity, it has therefore been
proposed that presenilins either modulate the activity of γ-secretase or both β-and γ-
secretase, or that  PS-1 itself is γ-secretase ( Haas and De Strooper 1999, Russo et al.
2000).
In addition, the presenilins appear to control the proteolysis of the membrane-
associated proteins of integral membrane domains of APP, of Notch, of the mamma-
lian APP homolog of amyloid precursor-like protein 1 (APLP-1) and of the tyrosine
kinase receptor (TrkB) (De Strooper et al 1998, DeStrooper et al. 1999, Naruse et al.
1998 ).
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4.  FAMILIAL DISEASES CAUSING DEMENTIA AND SPASTIC
PARAPARESIS
4.1.  Prion diseases
4.1.1.  Familial Creutzfeldt-Jakob disease (FCJD)
Clinical features in Creutzfeldt-Jakob disease (CJD) are often preceded by a prodomal
period of non-specific features such as fatigue and sleep disturbance.  However, the
most characteristic features include rapid mental deterioration, myoclonus, motor
disturbance (extrapyramidal, cerebellar, pyramidal, and/or anterior horn cell), and an
electroencephalogram (EEG) showing periodic short-wave activity (DeArmond et
Prusiner 1998).  The peak age of onset is about 60 in sporadic CJD, while in FCJD
the onset is often earlier, about  46 to 55 (Brown et al. 1991).
4.1.2. Gerstmann-Sträussler-Scheinker disease
Gertmann-Sträussler-Scheinker disease (GSS) is an autosomal dominant disorder
caused by certain mutations of the prion protein gene.  Codon 105 mutation (P105L)
is associated with a clinical picture of spastic paraparesis (Ghetti et al. 1995).  Pa-
tients become affected in their fourth or fifth decades.  The clinical course is long
(9±3 years), progressing from paraparesis to quadriparesis, loss of emotional control,
and dementia.  In contrast to most other prion diseases, in GSS the EEG remains
normal, and neuropathological analysis shows no spongiform changes (Ghetti et al.
1995).
4.2.  Hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) comprises a clinically and genetically diverse
group of disorders characterized by insidiously progressive lower extremity weakness
and spasticity.  HSP is also known as familial spastic paraparesis and Strumpell-Lor-
rain syndrome (MIM *18260; Fink et al. 1996).  The prevalence of HSP in Europe
varies in different studies from 2.0 to 9.6/100 000 (McDermott et al. 2000).  Al-
though there are patients with HSP in Finland, the exact prevalence has not been
studied.  Based on their clinical features, patients with HSP are divided into two
groups, depending on whether the disorder is a pure spastic paraplegia (uncomplicat-
ed HSP) or a more complex syndrome with other codominating findings (complicat-
ed HSP) (Harding 1981).  Uncomplicated HSP is limited to spastic gait, urinary
tract symptoms, lower extremity hyperreflexia, clonus, extensor plantar responses,
and often mildly impaired vibration sensation in the distal lower extremities with
little or no involvement of the upper limbs (Harding 1981, Heinzlef et al. 1998,
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Scheltens et al. 1990, McDermott 2000, Fink 2000).  The major neuropathological
feature in HSP is axonal degeneration that is maximal in terminal portions of the
longest descending and ascending tracts within the spinal cord (Behan and Maia
1974).  The most severely affected pathways are the crossed and uncrossed corticospi-
nal tracts going to the lower extremities and the fasciculus gracilis fibers coming
from the lower extremities (Harding et al. 1981, McDermott et al. 2000).  These de-
generating axons are the longest axons in the central nervous system (Fink et al.
1996).  In addition, involvement of spinocerebellar tracts is seen in about 50% of
cases (McDermott et al. 2000).
In complicated HSP, other abnormalities may include optic atrophy, retinopathy,
extrapyramidal disturbance, supranuclear gaze palsy, cerebellar signs, epilepsy, ichty-
osis, mental retardation, and deafness (Cross and McKusick 1967, Fink et al. 1996,
McDermott et al. 2000).  The psychiatric symptoms associated with complicated
HSP are mental retardation, presenile dementia, and hypomania (Skre 1974, Primore
et al. 1995).  Complicated HSP with dementia is probably not as rare as earlier
thought.  Recent studies have suggested that this kind of HSP is linked to chromo-
some 2p and is associated with a subcortical type of dementia (Webb et al. 1998,
McDermott et al. 2000).  In a chromosome 2p21-24-linked family the patients de-
veloped late onset dementia, and autopsy confirmed specific cortical pathology, maxi-
mal in the hippocampus and medial temporal cortex.  There were neuronal depletion
and tau-immunoreactive neurofibrillary tangles in the hippocampus and frequent
balloon cells seen in the limbic system and neocortex (White et al. 2000).
HSP may be transmitted in an autosomal dominant, autosomal recessive, or X-
linked recessive manner (Behan and Maia 1974, Fink 2000).  At present, mutations
in four genes: L1CAM, PLP, paraplegin, and spastin have been identified to underlie
an HSP phenotype, while the genes at seven other loci remain unknown (McDermott
et al. 2000).  Inheritance of HSP is most commonly autosomal dominant, and the
phenotype has been linked to loci on chromosome 2p, 14q, 15q, 8q, 10q, and 12q,
but not all families map to these loci (Hazan et al. 1993, Fink et al. 1995,
McDermott et al. 2000).  The most common locus of autosomal dominant HSP is
chromosome 2 (Webb et al. 1998, McDermott et al. 2000).  Recently mutations in a
gene called spastin has been identified in uncomplicated HSP and localized on
chromosome 2p22-p21 (Hazan et al. 1999).
Genetic loci for  autosomal recessive uncomplicated HSPs have been identified
on chromosomes 8p11-8q13 and 15q13-q15 (Fink 2000).  Mutations in a gene
called paraplegin on chromosome 16q24.3 have been found in autosomal recessive
complicated HSP (McDermott et al. 2000).  X-linked HSP is rare.  Families with
complicated HSP have been linked to Xq28 and Xq22, whereas  uncomplicated HSP
has been linked to Xq22 (McDermott et al. 2000).
4.3.  Familial British dementia (FBD)
Familial British dementia, previously known as familial cerebral amyloid angiopathy
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of British type, is clinically characterized by its autosomal dominant mode of inherit-
ance, progressive spastic tetraparesis, cerebellar ataxia, and dementia, with onset in
the sixth decade (Worster-Drought et al. 1940, Plant et al. 1990, Mead et al. 2000).
The first symptom in some patients is paralysis, whereas other patients only have de-
mentia (Worster-Drought et al. 1940).  In addition, cerebellar signs are typical.  Pa-
tients have, infrequent, indistinct, and progressively slurred speech. Less constant
clinical features include headaches, occasional stroke-like episodes, personality
changes and “blackouts” (Plant et al. 1990).  The mean age of onset of symptoms is
47 years (range from 40 to 57) and the duration of the disease ranges from 2 to 18
(Plant et al. 1990).
Extensive cerebral periventricular white matter changes visualized in MRI are
typical for FBD.  White matter changes are also seen in the brainstem and cerebel-
lum (Plant et al. 1990).  In neuropathological examination there is severe, extensive
amyloid angiopathy with deposition of amyloid in small cerebral and spinal arteries
and arterioles.  Three different types of plaques have been described.  Classified as
large, small, and perivascular (Plant et al. 1990, Revesz et al. 1999).  Large plaques
appear as large globular masses, often with a central congophilic star-shaped core and
peripheral radiating fine spicules or coarser processes.  Small plaques resemble the
central core of the large plaques, but are naked and show no peripheral pale zone.
Perivascular plaques appear as pale, homogenous, or fibrillated structures around
capillaries or arterioles.  They are faintly PAS-positive, but not uncommonly have a
strongly congophilic core.  Light and electron microscopic examination shows that
hippocampal amyloid plaques are primarily of the “nonneuritic” type (Plant et al.
1990, Revesz et al. 1999).  These nonneuritic amyloid plaques also affect the cerebel-
lum (Plant et al. 1990).  In addition, the presence of numerous neurofibrillary tan-
gles (NFTs) has been reported (Plant et al. 1990).
Neuropathological examination reveals myelin pallor in the pyramids of the me-
dulla oblogata (Plant et al. 1990).  There is mild pallor of myelin staining of the
gracile and cuneate fasciculi.  In addition, the corticospinal and dorsal and ventral
spinocerebellar tracts are affected (Plant et al. 1990).  Recently, a unique 4K protein
subunit called ABri has been isolated from the amyloid fibrils of FBD patients (Vidal
et al. 1999).  ABri is a highly insoluble peptide which is a fragment of a putative
type-II single-spanning  transmembrane precursor protein that is encoded  by a novel
gene, BRI, located on chromosome 13.
4.4.  Autosomal dominant Alzheimer’s disease and spastic
paraparesis
Spastic paraparesis is not a classical feature of AD.  However, a few case reports exist
of a rare combination of dementia and spastic paraparesis.  The earliest description of
the unusual combination of dominantly inherited Alzheimer-type presenile dementia
with spastic paralysis affecting members of a family in Belgium was published in
1940 (van Bogaert et al. 1940).
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Postmortem neuropathological analysis of the brain of one patient showed nu-
merous neurofibrillary tangles as well as a multitude of various types of senile
plaques not only in the cerebral but also in the cerebellar cortex.  In addition, “druse-
nartige Entartung” of cerebral blood vessels as well as degeneration of the pyramidal
tracts were observed (van Bogaert et al. 1940).  Alzheimer’s disease with either para-
or tetraparesis has also been reported in an Australian family (Kwok et al. 1997), in
one Japanese patient (Aikawa et al. 1985), and in two Japanese sisters (Sodeyama et
al. 1995 ).  After the publication of our first article (IV), several other families with
presenile Alzheimer’s disease and spastic paraparesis have been described (see Discus-
sion, Table II).
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AIMS OF THE PRESENT STUDY
The purpose of this study was:
1.  To define the clinical and neuropsychological features of a novel
variant of presenile familial Alzheimer’s disease called variant
Alzheimer’s disease (varAD) (I,II)
2.  To describe the neuropathological features associated  with variant
Alzheimer’s disease (III)
3.  To establish the molecular genetic basis of variant Alzheimer’s dis-
ease in a Finnish family (IV, V)
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PATIENTS AND METHODS
1.  PATIENTS
The study family was ascertained through a family member who contacted The
Family Federation of Finland in the 1980’s requesting genetic counseling because of
a strong family history of an early-onset dementia combined with impaired gait.
The pattern of transmission was compatible with autosomal dominant inheritance of
full penetrance, but the precise diagnosis was unknown.  When this study began in
1996, sixteen affected relatives had been identified in four generations of the family,
and three of them were still living.  Further pedigree information came from family
members, medical records, and parish registers.  The first affected individual had
been born in 1860 in southern Finland.  One branch of the family was discovered in
1997 when her typical cotton wool plaques were identified.  This patient had not
been in any contact with her relatives.  Three new patients started to show symptoms
during this study.  Finally, 23 affected individuals (16 males and 7 females) were
identified (Figure 1).  Medical records were available for 15 and six of them were
personally examined.  Additional evaluations such as functional imaging and
neurophysiologic investigations were performed at the neurological departments of
four university hospitals in Helsinki, Turku, Tampere, and Oulu.  All PET imaging
was performed at the Turku PET Center.  Molecular genetic analysis was completed
for samples sent to the Neurogenetic Laboratory, Mayo Clinic, Jacksonville, Florida.
Medical and neurologic records were available from nine additional deceased
patients.  Eight other patients had had a history of a similar disorder, but medical
records were  unavailable.  These 17 patients, plus the previous 6 patients comprise
the 23.  This study includes data on neuropathologic autopsies performed on five
cases of the 15 cases (Table 1).
To date this is the only family with presenile dementia and spastic paraparesis that
has been identified in Finland.
2.  ETHICAL ISSUES
This study was approved by the Ethics Committees of  the Department of Neurology
of the Helsinki University Central Hospital and the Family Federation of Finland.
Patients or their caregivers gave written consent for participation in the study.  Be-
cause the blood samples were collected for research purposes family members were
told not to expect individual  results.  After the mutation was found they received an
information letter recommending that they contact a genetic counseling clinic in
case they would consider presymptomatic testing.  In that case, a new blood sample
would be taken.
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For reasons of confidentiality, the family tree has been modified, and no pedigree
symbols for gender have been used.
3.  CLINICAL METHODS (I, II)
3.1.  Neurologic examination
A total of eleven family members (six affected and five non-affected individuals) were
personally examined.  The function of their cranial nerves was investigated, and men-
tal status, motor function, gait, tendon reflexes, and sensation were examined.
3.2.  Neuropsychological examination
A comprehensive neuropsychological test battery was administered to four of these
six affected.  In addition, retrospective neuropsychological data were collected from
four other cases (during the years 1982 to 1998).  Patients’ ages ranged from 43 to
63 years at the time of testing, and duration of illness from the first symptoms
ranged from 0 to 6 years.  Severity of the disease ranged from the mild to the moder-
ate stage.  The four retrospective cases were examined once, whereas the other four
patients took part in the follow-up of two successive examinations.  The neuropsy-
chological evaluation was based on tests of verbal and visual memory, abstract think-
ing, visuoconstructional and spatial functions, language ability, calculation, and tasks
of ideomotor apraxia.  Orientation was assessed by the Orientation questions of the
Wechsler Memory Scale (WMS) (Wechsler 1945).  Memory tests included Logical
Memory (story A) and Visual Reproduction (pictures A and C) of the WMS-Revised
(Wechsler 1987).  A 10-word learning test was administered to most of the patients
(Christensen 1975, Erkinjuntti et al. 1986 ).
Abstract thinking was evaluated by the Similarities Test form the Wechsler Adult
Intelligence Scale (WAIS of Wechsler 1955:  items 1-4, 6, 8, 9, 12, 13).  Visuocon-
structive Abilities were measured by Block Design from the WAIS (Wechsler 1955):
items 1, 2, 4-10, and copying a cube (Christensen 1975, Erkinjuntti et al. 1986).
Calculation included either mental arithmetic from a dementia test (Christensen
1975, Erkinjuntti et al. 1986) or basic paper and pencil arithmetical problems used
in clinical settings.  Apraxia of hand movements was mainly evaluated by the recip-
rocal and spatial tasks from the Dementia test (Christensen et al. 1975, Erkinjuntti
et al. 1986) and by Finger Tapping.  A cohort of 13 healthy individuals were selected
as case-controls on the basis of age, education, and gender.  In sporadic AD, because
age of onset is approximately 20 years later; such patients were not considered appro-
priate as controls.  Healthy control subjects were recruited from a study examining
sporadic dementia (Erkinjuntti et al. 1986).
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3.3.  Psychiatric evaluation
Psychiatric symptoms of eight of the 23 patients were evaluated by specialists in
clinical psychiatry and neurology with particular attention to emotions and to mood
disturbances such as depression, euphoria, anxiety, delusions, and hallucinations.
3.4.  Cerebrospinal fluid (CSF) analysis
Cerebrospinal fluid was taken from nine patients by standard procedures.  Protein
level, cell counts of white and red blood cells, and glucose of CSF were analyzed.
3.5.  Neurophysiologic studies
Conventional EEG recordings were taken of 9/15 affected individuals.  Five EMG
and nerve conduction studies were performed.  Visual evoked potentials (VEP) stud-
ied in one patient and somatosensory evoked potentials (SEP) were performed on
three patients.
3.6.  Neuroimaging
Cranial CT:s were done on nine affected individuals and on three non-symptomatic
relatives at risk for the disorder.  An MRI system operating at 1.5T (GE, Signahorit-
zon) was used.  All four individuals subjected to brain MRI were affected.  In addi-
tion, spinal MRI was carried out on these four plus one patient.  Before MRI was
available, myelography had been performed on four patients with spastic paraparesis,
whereas SPECT (99mTc-HM-PAO) had been performed on four patients by standard
methods.
PET in addition to MRI was performed on the four patients with a GE (Milwau-
kee, WI, USA) advance scanner giving 35 transaxial planes at 4.3 intervals.  2-[18F]-
fluoro-2-deoxy-D-glucose (FDG) served as a ligand.  FDG was prepared as described
(Hamacher et al. 1986, Solin et al. 1988); radiochemical purity exceeded 99%, and
specific radioactivity at the time of injection was about 75 Gbq/mmol.  A dynamic
55-minute study was performed after intravenous injection of a bolus of 3.7 MBq/kg
of FDG.  Arterialized blood samples were drawn from the antecubital vein to meas-
ure plasma radioactivity concentration and glucose level.  The four patients studied
by PET took part in a neuropsychological follow-up study.
4.  NEUROPATHOLOGICAL METHODS (III)
A neuropathological autopsy on five patients was performed 5-48 hours after death
(with the exception of case III:20); these were three males and two females.  Age at
death ranged from 54 to 69 years and disease duration from 5 to 12 years.  The im-
mediate cause of death was bronchopneumonia in four of these cases and pulmonary
thromboembolism in one case.  Four of these patients had suffered spastic paraparesis
with presenile dementia; one suffered presenile dementia alone without definite evi-
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dence of paraparesis.  The brains and spinal cords of all five deceased patients were
fixed in 4% phosphate-buffered formaldehyde.
4.1.  Histology and immunohistochemistry
Representative tissue samples from frontal, temporal, parietal, and occipital associa-
tion cortices, the precentral motor cortex (both lateral and interhemispheric aspects),
hippocampus, amygdala, basal ganglia, midbrain, cerebellum, pons, medulla, and
spinal cord were embedded in paraffin.  The samples were stained with the hematox-
ylin-eosin (HE), periodic acid-Schiff (PAS), Luxol Fast Blue-cresyl violet (LFB-CV),
and modified Bielschowsky stains.  Amyloid was identified after Congo red staining
(Puchtler) by red-green dichroism in polarized light and by fluorescence after thiofla-
vin S staining.  Selected specimens were studied after appropriate pretreatments by
standard immunoperoxidase methods for the presence of APP, various APP-derived
peptides, hyperphosphorylated (PHF) and non-phosphorylated tau protein, neurofila-
ment peptides, synaptophysin, ubiquitin, apoE, amyloid P-component, protease-re-
sistant prion protein, and complement components, as well as for markers of macro-
and microglia.  The bound primary antibodies were visualized by use of an appropri-
ate peroxidase-labeled secondary antibody (Vector Laboratories, Burlingame, CA,
USA) with diaminobenzidine as the chromogen and hematozylin as the counterstain.
4.2.  Confocal microscopy
Paraffin sections of various thickness (5 to 20 µm) were doubly immunostained with
polyclonal rabbit antisera raised against Aβ1-40, Aβ1-42, or Aβ1-43, and mouse
monoclonal antibody against neurofilament or to PHF-tau.  FITC-conjugated goat
anti-mouse and TRITC-conjugated swine anti-rabbit secondary antibodies were used
to label the bound primary antibodies.  The sections were viewed under a Leica TCS
SP confocal microscope with version 1.6.587 software, and the pictures were edited
with the Adobe Photoshop 5.5 program.
4.3.  Electron microscopy
For electron microscopy, samples were taken from the cerebral cortex of brains rou-
tinely fixed in 4% phosphate-buffered formaldehyde.  After postfixation with os-
mium tetroxide, the samples were dehydrated and embedded in epon.  Semi-thin
sections were stained with toluidine blue.  Regions of interest were selected for the
cutting of thin sections which were contrasted with uranyl acetate and lead citrate
and examined in a JEOL JEM 1200 electron microscope.
4.4.  Biochemical analyses
Aβ40 and Aβ42 were extracted from fresh-frozen brain tissue of two patients (III:16,
III:17) autopsied 14 and 5 hours post mortem, captured using BNT77 antibody, and
detected by use of BA27 HRP (for Aβ40) and BC05HRP (for Aβ42) antibodies with
peroxidase substrate/solution (Tomita et al. 1997)
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5.  MOLECULAR GENETIC METHODS (IV, V)
5.1.  Linkage analysis
DNA was extracted from whole blood samples of patients and healthy family mem-
bers.  Markers were chosen  from the vicinity of  three genes, the APP, the PS-1, and
the PS-2 gene.  The  PS-1 gene was the only gene that preliminary showed weakly
positive lod scores.
Linkage analysis was performed of markers from around the PS-1 gene.  The fol-
lowing markers were used: D14S277, D14S268, D14 S77, 2 cM gap, D14S71, 2 cM
gap, D14S43, D14S273, D14S284, 12 cM gap and D14S256.  The lod score was cal-
culated with MLINK (http://linkage.rockefeller.edu/soft/list.html#m) set at a mu-
tant allele frequency of 0.01, a disease frequency of 0.01, and full penetrance by age
60.  Genetic data using D14S77 was generated by an ALF-Pharmacia sequencer
(Uppsala, Sweden) and analyzed with the Linkage baggage programs.  These data
were compared with simulation data generated for the pedigree by SIMLINK.
5.2.  Analysis of cDNA
To analyze the PS-1 gene in more detail, RNA was isolated from immortalized lym-
phoblastoid cell lines withTrizol Reagent (Gibco BRL, Pittsburgh, PA, USA) follow-
ing the manufacturer’s protocol.  First strand cDNA was obtained with the Super-
Script preamplification system ( Gibco  BRL) and a gene specific primer (5’-GT-
TCGCAGTGTGCAGTGAAATCG-3’) designed toward the 3’ end of PS-1 in exon
12.  The target cDNA was amplified by use of 4 different primer pairs spanning var-
ious exons, designed to give products of ~700bp.
Primers in exon 5 (5’-CTGAATGCTGCCATCATG-3’) and exon 10 (5’-TGCT-
GGAAAGTTCCTGGAC-3’) gave alternately spliced products which were isolated
from an agarose gel with a QIAquick gel extraction kit (Qiagen).  Purified products
were sequenced on an ALF automated sequencer (Pharmacia) using exonic fluores-
cently labeled primers and Thermosequenase cycle sequencing kit (Amersham, UK).
5.3.  Defining the mutation
To characterize the ∆9 deletion at genomic level, intronic primers flanking exon 9
were designed to use the PAC sequence available in the Genebank sequence database
(clone DJ0054D12; accession number AC006342).
Western blotting was used to analyze PS-1 ∆9 mutant protein expression in hu-
man lymphoblasts.  Lymphoblasts grown in RPMI 1640 medium (Gibco) supple-
mented with 15% FBS and antibiotics were harvested, washed, and then lysed by
brief sonication in lysis buffer (2% SDS in Tris buffered saline PH 7.8 containing a
cocktail of protease inhibitors).  Fifty micrograms of total lysate protein was loaded
and separated on 10% tricine gels, transferred to immobilon, and probed with PS-1
antibody against residues 2 to 12.
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5.4.  ApoE genotyping
In five patients, APOE alleles ε2, ε3, and ε4 were detected following standard PCR
and RFLP methods.  Briefly, a 231 bp fragment of the APOE gene including sites of
the ε2 and ε4 variants was amplified in a 25 µl PCR reaction containing 1.5 mM
MgCl
2
, 150 µM dNTPs, 0.3 µM of each primer, 10% dimethyl sulfoxide (DMSO),
and 0.5U Taq DNA polymerase (Promega).  Amplification was done by a 60-50
touchdown protocol.  PCR products were digested with 3U of Hha I enzyme for 4
hours, and then the DNA fragments were separated on a 4.5% agarose gel after
ethidium bromide staining.  The APOE genotype was determined by the pattern of
DNA fragments present (Crook et Duff 1994).
6.0  Statistical analysis
The level of significance of the differences between mean ages at onset and ages at
death of affected men and women were analyzed by the ANOVA test with the SPSS/
PC (Cary, NC, USA) program.  Neuropsychological test results between our patients
and control subjects were compared by the Mann-Whitney U-test.  P values of less
than 0.05 were accepted as significant.
RESULTS
1.  CLINICAL FINDINGS
1.1.  Pedigree analysis
The distribution of affected individuals within the pedigree was compatible with an
autosomal dominant mode of inheritance with full penetrance.  Among the 23 affect-
ed subjects, the male/female ratio (16/7) was 2.28.
1.2. Clinical course
The age at onset of varAD symptoms ranged from 40 to 61 years, the mean age
(±SD) being 50.9±5.0 for all affected individuals.  Age of onset for men was 50.7
±5.4 and 51.3 ±4.9 for women.  All patients had dementia usually preceded by or
co-existing with spastic paraparesis.  In patients (11/15) with spastic paraparesis, it
preceded dementia by approximately 5 years. Impaired gait appeared at age 45 to 60.
The course of spastic paraparesis was progressive, and most patients needed some
kind of walking aid.  In the late stage of the disease, all patients were bedridden.
They were also mute, incontinent, and unable to cooperate.  Furthermore, some pa-
tients developed flexion contractures, lower facial weakness, and difficulties in swal-
lowing.  The duration of the disease from onset of symptoms to death was 9 years on
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average (range 5 to 12 years), with mean age at death (± SD) being 60.7 ± 5.8 years
for all patients, 62.3± 4.5 for men, and 58 ± 7.4 for women.  The immediate cause
of death in most patients was bronchopneumonia.
1.3.  Neurological signs
1.3.1.  Dementia
Dementia was the neurologic sign shared by all affected individuals.  They had diffi-
culties in immediate and delayed recall of recently presented material.  Progressive
loss of memory was diagnosed by the age of 40 to 61.  In addition, all patients had
other neuropsychological deficits such as impairment of spatial skills, apraxia, acalcu-
lia, and aphasia.  Both memory deficit and impairment of other cognitive functions
progressed, causing dementia in all patients.  Thus only three patients of the fifteen
maintained some insight into their cognitive decline.
1.3.2. Spastic paraparesis
Spastic paraparesis was the second most common and the most characteristic clinical
feature of variant AD.  Furthermore, spastic paraparesis was often the first symptom
of the disease preceding dementia.  In some patients, however, spastic paraparesis ap-
peared simultaneously with dementia; while dementia preceded it in one case only.
Age at onset of paraparesis was 45 to 55 years, and most patients were referred to a
neurologist for impaired gait.  Reliable medical data were available for 15 of 23 af-
fected individuals.  A total of eleven patients (three personally examined) had spastic
paraparesis verified by medical examination (Table 1).  Six of them had subjective ex-
perience of one leg’s being weaker than the other, but the neurological examination
revealed that all patients had bilateral spastic paraparesis.  Of eleven patients with
spastic paraparesis, five became wheelchair-bound after 6 years on average (range 5 to
8 years), and three further patients used crutches. Six patients with spastic parapare-
sis suffered lower back pain about 1.5 to 5 years before their gait disorder.  Two of
these had retired because of severe chronic back pain before the manifestation of oth-
er symptoms.  Neurologic examination of patients with disturbed gait showed hyper-
reflexia or clonus of the lower extremities.  Furthermore, in most cases the Babinski
response was abnormal on both sides.  Sensation in the trunk remained normal.  Ex-
cept for three patients of whom two had polyneuropathy, sensation in the extremities
also remained normal.  Of the 15 patients, four developed no spastic paraparesis.
However, three of these were personally examined, and in neurological examination
two of them showed unusually brisk knee and ankle jerks.
1.3.3.  Clumsiness of the hands and dysarthria
Ten of the 15 affected individuals showed clumsiness of the hands, six of them also
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had paraparesis.  Neurologic examination revealed hyperreflexia in ten of whom spas-
ticity of the upper extremities appeared in three.  In most cases, clumsiness of the
hands was present bilaterally.  In three of the 10, the clumsiness was so severe that it
complicated activities of daily life.  In the late stage of the disease, these three pa-
tients were unable to move their left hands but were able to use their right.  Howev-
er, no tetraparesis in the sense of inability to move all four extremities was seen.
Dysarthria was noted in six of the fifteen patients.
1.3.4.  Other clinical findings
Of 14, seven patients had motor dysphasia that progressed to aphasia.  Only two of
the 15 had myoclonus.  One had myoclonus in the body and the extremities seven
years after of onset,  and the other already had facial myoclonus at the onset of the
disease.  Three patients had gaze palsy resembling the supranuclear pathway type.
They had difficulties in following a moving object, especially upwards.  Epileptic
seizures of the grand mal type were diagnosed in four.  However, epilepsy was not an
early sign; it was seen from five to ten years after onset of the first symptoms.
1.4.  Neuropsychological findings
The patients showed statistically a significant cognitive decline in all tests: orienta-
tion, logical memory, visual reproduction, similarities, Block Design, and copying a
cube.  All except one patient had difficulties in orientation.  Furthermore, immediate
recall in Logical Memory in most of the patients was reduced to two or three items.
Visual Reproduction was impaired, and the patients were able to learn only five to
seven of the ten words presented in the Learning test.
All patients had difficulties in intellectual functions.  However, abstract think-
ing, measured by the Similarities test, showed some variability and fell within the
normal range in two patients.  The most characteristic feature besides memory defi-
cits was early and prominent impairment of visuoconstructive functions.  Conse-
quently, all patients had difficulties in the Block Design test.  In addition, most pa-
tients also showed impairment of spatial functions.  Two of the eight patients could
copy a cube and a cross, but had difficulties in the Block Design, while others could
not produce copies and were almost incapable of placing the cubes in Block Design.
There was variation concerning impairment in language functions and calcula-
tion.  One patient developed aphasia, while others showed only mild language diffi-
culties.  Difficulties in calculation was not a prominent feature.  However, all pa-
tients exhibiting apraxia, when tested, showed ideomotor apraxia.  Four patients
took part in a follow-up study including neuropsychological examination, and the
findings correlated with findings in PET (see 1.8.4.).
Patient IV:1, who had least cognitive difficulties, showed progression only in
memory, visuoconstructional functions, apraxia, and executive functions.
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1.5.  Psychiatric signs
Among the 23 affected family members, eighth patients had a combination of de-
mentia and psychiatric symptoms.  The psychiatric symptoms showed great variabil-
ity: In general, the most typical were emotional lability and mood disturbances.
Three patients suffered from mild to moderate depression.
One patient experienced depression with anxiety, while another one had depres-
sion alone.  The third patient experienced depression in the early stage of her disease,
but as the disease progressed, she suffered from delusions and visual hallucinations.
In contrast, two patients developed abnormal euphoria.
1.6.  Cerebrospinal fluid (CSF) findings
CSF was available for nine patients.  In all samples, the cell count and glucose level
of the CSF were normal.  In contrast, the protein concentration was elevated in five,
with a range of 490 to 971mg/L (normal range, 150-450mg/L).  Four of these five
patients had spastic paraparesis.
1.7.  Neurophysiologic findings
1.7.1.  EEG
In this study, a total of nine conventional EEG recordings of affected individuals
were taken.  All EEGs were abnormal, consisting of the sporadic generalized slow
delta-theta activity (3-4 Hz) that is frequently seen in the severe stage of AD.
1.7.2.  EMG
Of the five EMG and nerve conduction studies performed, three indicated mild distal
sensorimotor polyneuropathy; one patient also had diabetes, while the etiology for
polyneuropathy in two patients remained unknown. However, in all these cases
polyneuropathy was very mild and thus could not have explained the impaired gait.
One examination was abnormal in an unspecified way.
1.7.3.  Somatosensory evoked potentials
Visual evoked potentials (VEP) was performed on one patient, and the results were
normal; somatosensory evoked potentials (SEP) performed on three showed normal
results, with the exception of one patient with polyneuropathy.
1.8.  Findings in imaging studies
 Most of the nine CTs of the head showed both central and cortical atrophy.  In addi-
tion, some incidental old infarcts without clinical relevance were detected. Cortical
atrophy ranged from moderate to severe.  The hippocampal region was particularly
atrophied.  All three cranial CTs done on healthy family members were normal.
Myelographies had been done on four patients with spastic paraparesis.  Two of
these had lumbar spondylosis and one was operated on for a diagnosis of spinal steno-
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sis.  However, because his spastic paraparesis deteriorated also after the operation,
this indicated that spinal stenosis was not the true cause of his spastic paraparesis.
Myelography of two other patients with spastic paraparesis revealed no significant
abnormality
Results of a SPECT scan taken of four patients in the early stage of the disease
were normal.
PET showed temporo-parietal hypometabolism compatible with AD in all four
patients scanned.  Variable patterns of  additional hypometabolism areas were related
to individual deficits in cognitive performance. Temporo-parietal hypometabolism
was the only PET finding in one patient who was in the early stage of the disease but
already had spastic paraparesis and slight difficulties in logical Memory, Visual Re-
production, and Block Design tests.
1.8.1.  PET and neuropsychological follow-up
The PET scan of patient III:24 demonstrated widespread bilateral hypometabolism
in the temporo-parietal areas, with slight hypometabolism noted also in the occipital
cortex; the frontal cortex and striatum were relatively preserved.  This patient already
had severe visuoconstructive and spatial difficulties in the first testing, and these def-
icits progressed into visual agnosia in the follow-up of 5 years and 8 months.  The
patient was able to identify common objects, but not simple drawings.  Although
progression in all cognitive domains were noticeable, the most prominent features
were memory and visual impairments.  The PET scan of patient III:25 showed hy-
pometabolism in temporal and parietal areas bilaterally, but more clearly on the
right.  He had memory problems, and his visuconstructive abilities were poor.  The
PET scan of patient IV:2 showed bilateral hypometabolism in the temporal and pari-
etal cortices, but more severely on the left.  He showed severe memory impairment
and progressive dysphasia, despite only mild to moderate difficulties in visuocon-
structive and spatial functions. At the follow-up seven months later, his memory per-
formance had slightly deteriorated, and progressive aphasia caused impairment in the
Similarities test.
2.  NEUROPATHOLOGIC FINDINGS
2.1.  Macroscopic observations
Post-mortem brain and spinal cord tissues from five patients were available for neu-
ropathological analysis.  At macroscopic neuropathological examination, the brain
weights ranged from 1075 g to 1475 g, the highest weight (1470g) being due to
marked brain edema.  Except for the patient with brain edema there existed moder-
ate to severe generalized cerebral gyral atrophy and pronounced shrinkage of the me-
dial temporal lobes.
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In addition, there was atrophy of the hippocampi and, at most, slight atheroscle-
rosis of the intracranial arteries.  One patient (III:16) had suffered an old left frontal
intracerebral hemorrhage which was of the lobar type.
2.2.  Histologic findings
2.2.1.  General description
Histopathologic analysis of the brains of these patients showed unexpected but char-
acteristic features.  The cerebral isocortex both the primary cortex and association
cortices, including the precentral motor cortex showed numerous plaques.  Several
types of plaques occurred, but one type predominated.  Because of their characteristic
morphology, the predominant ones were termed “cotton wool “ plaques (CWP).  In
addition to these CWPs, variable numbers of diffuse and cored plaques appeared in
the cerebral cortex.  The number of plaque-related macro-and microglial cells was
small.  However, although neuronal loss was observed in all areas of isocortex, it was
particularly pronounced in the hippocampus and entorhinal cortex.  Amyloid angio-
pathy was present in the meningeal and cortical blood vessels and it was particularly
extensive in the precentral cortex and in the cerebellum.  Diffuse and nonneuritic
cored amyloid plaques appeared in the cerebellum.  Degeneration of the lateral corti-
cospinal tracts was observed at the level of the medulla oblongata and the spinal
cord.
2.2.2.  Plaques
CWPs were the most prominent neuropathological change of varAD.  They were
eosinophilic structures with distinct borders but devoid of a congophilic core.  Fur-
thermore, they were unusually large, their diameters often exceeding 100 µm.  These
CWPs were immunoreactive for Aβ but, in contrast to neuritic and amyloid plaques,
they did not, after thioflavin S staining, show congophilia/red-green dichroism or
bright fluorescent cores.
In silver impregnation, only minor plaque-associated neuritic pathology was evi-
dent. Interestingly, CWPs did not stain for the amyloid P-component and only in-
consistently and minimally for ApoE and the complement components C1q, C3d,
and C9.  Their immunoreactivity for synaptophysin was accentuated in comparison
with the surrounding neurophil.  The CWPs avidly bound antibodies raised against
Aβ1-16, Aβ42, and Aβ43 but were weakly nor not at all visualized by antibodies
raised against Aβ40.
Individual CWPs were frequently composed of homogeneous granular material
only, but several of them embraced macro-and microglial cells or neuronal perikarya.
Macro-and microglial cells, as identified by GFAP or HLA-DP, DQ, DR immunopo-
sitivity, were very rarely seen in association with CWPs when compared with other
forms of AD.
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The density of axons within individual CWPs was usually markedly reduced
when compared to those of the surrounding neurophils, as demonstrated by silver
impregnation, LFB-CV, and double immunostaining for Aβ peptide and neurofila-
ment proteins, including analysis with the confocal microscope.  Most of the axons
seemed either to wind around the CWP or degenerate on entering the CWP.
CWPs were most commonly separate from each other but  sometimes coalesced
and formed conglomerates.  Especially large conglomerates of CWPs occurred in the
interhemispheric precentral cortex, corresponding to the motor representation of the
lower extremities, whereas the lateral motor cortex showed fewer CWPs.  CWPs
were common in all deep layers of the cortex (III to VI).  Occasional CWPs were also
detected in the subcortical white matter and a few even deep in the white matter.
They were also present in the amygdala, putamen, globus pallidus, and claustrum.
CWPs were frequent in the entorhinal cortex and hippocampus.  They were par-
ticularly abundant in the subiculum, and displaced neurons and even interrupted and
distorted the granular cell layer of the dentate gyrus and the pyramidal cell band of
the hippocampus.  No CWPs were present in the cerebellum.
In the cerebral cortex, in addition to the CWPs, there appeared diffuse plaques
and cored and non-cored plaques with dystrophic or PHF type neurites.  However,
CWPs were always the predominant type of plaques, with the relative proportions of
other types of plaques varying among different cortical regions and individual pa-
tients.  The number of cored plaques was highest in patient III:16, who had suffered
an intracerebral hemorrhage.  However, even in this patient, CWPs were predomi-
nant in the deeper cortical layers.
2.2.3.  Neurofibrillary pathology
Only a few silver- or hyperphosphorylated tau (PHF-tau)-positive dystrophic neurites
were associated with CWPs.  Even the number of neurophil threads in the isocortex
was relatively low.  In contrast, neurons bearing neurofibrillary tangles (NFT) were
common in the isocortex and comprised the majority in the entorhinal cortex and
hippocampus.  Apart from NFT, no tau-or ubiquitin-immunoreactive intraneuronal
or glial inclusions were observed.
2.2.4.  Amyloid angiopathy
Amyloid angiopathy was present in the meningeal and cortical blood vessels in all
autopsied patients.  Extensive congophilic amyloid deposits, immunoreactive for Aβ,
were seen in the walls of these vessels.  After thioflavin S staining, the vascular amy-
loid deposits were strongly fluorescent in ultraviolet light.  Amyloid angiopathy was
particularly prominent in the cerebellum.  In addition, there was a discontinuous
subpial layer of Aβ-immunoreactivity in a band-like pattern.
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2.2.5.  Cerebellar pathology
There were no CWPs found in the cerebellar cortex.  Instead, there were scattered
amyloid plaques with compact cores in the molecular layer.  These plaques were
strongly immunoreactive for both Aβ40 and Aβ42/43 and were surrounded by a halo
of Aβ42/43 positivity.  These cored plaques were associated with clusters of micro-
glial cells.  In addition, in all three layers of the cerebellar cortex were numerous ir-
regular diffuse plaques, which were immunopositive for Aβ42/43 but not for Aβ40.
No obvious difference was observed between the vermis and the hemispheres.  PHF-
tau-positive material was absent from around the cerebellar plaques.
2.2.6.  Brain stem and spinal pathology
In the medulla oblongata and spinal cord, Luxol Fast Blue (LFB) and neurofilament
stainings disclosed a marked loss of myelin and axons in the corticospinal tracts.
Immunoreactivity for Aβ was observed only as occasional small diffuse plaques in
the central gray matter of the cord, whereas the tracts in the white matter were Aβ-
negative.  No PHF-tau-positive perikarya or neurites were encountered in the spinal
cord.
2.3.  Electronmicroscopic findings
At the ultrastructural level in electron microscopy, apart from occasional elongated
structures amongst the granular osmiophilic material, no definite filaments to sug-
gest presence of fibrillar amyloid were detected within the CWPs. In the markedly
thickened blood vessel walls, abundant bundles of straight non-branching filaments
with a diameter of about 10 nm, corresponding to amyloid fibrils, were present in
the lamina elastica interna and media where smooth muscle cells were destroyed.
2.4.  Biochemical findings
Biochemical analyses of the brain tissue were available for two cases (III:16, III:17).
These analyses disclosed exceptionally high  total Aβ concentrations.  Furthermore,
in the frontal lobes the concentrations of Aβ40 were 3.88 and 22.53µg/g, and those
of Aβ42 were 9.55 and 14.90 µg/g.  These values are markedly higher than the re-
ported concentrations of Aβ40 (1.66 µg/g) and Aβ42 (3.14µg/g) in sporadic AD
(Houlden et al. 2000).
3.  MOLECULAR GENETIC FINDINGS
3.1.  Linkage analysis
Linkage analysis of genetic markers from the vicinity of the APP and PS-2 genes
showed multiple examples of non co-inheritance with the disease, ruling out a muta-
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tion at either of these two loci.  Linkage analysis of markers from around the PS-1
gene were inconclusive because all patients and some unaffected individuals carried
the same haplotype.
However, modest positive two-point lod scores were obtained with several mark-
ers around PS-1.  Based on these lod scores, SIMLINK analysis suggested that the
family had prior odds of having a lesion on chromosome 14q24.3 of  more than 85%.
3.2.  Analysis of cDNA
RNA was prepared from isolated lymphoblasts.  The structure of the cDNA of the
PS-1 gene was examined through RT-PCR, showing a deletion of exon 9 in the PS-1
gene.  Furthermore, resequencing of the intron-exon boundaries of exon 9 confirmed
that there was no splice site mutation.
3.3.  Defining the mutation
Intronic primers flanking exon 9 were used.  In this final analysis, an approximately
6.5 kb region encompassing exon 9 showed the presence of an aberrant product that
was present in all patients’ samples but not in healthy family members’ samples and
not in more than 150 alleles of a Finnish control population.  This band was con-
firmed by sequencing to be the result of a 4,555 bp deletion between exons 8 and 10
and encompassing exon 9.
In Western blotting, the ∆9-PS-1 protein was not proteolytically cleaved, and
lysates from lymphoblasts expressing this mutation resulted in a truncated 39-kb
protein and a reduced amount of the endogenous 28-kd N-terminal fragment.
3.4.  ApoE genotypes
Three of five patients whose apoE genotype was analyzed had the most common gen-
otype ε3/ε3, and two patients had the genotype ε2/ε3 (Table 1).  These apoE geno-
types did not explain the variation in age at onset.
DISCUSSION
1. CLINICAL PHENOTYPE (I)
The earliest description of the combination of dominantly inherited Alzheimer-type
presenile dementia and spastic paraparesis was published in 1940 (van Bogaert et al.
1940). Offspring of this Belgian family have not been found, and therefore molecular
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genetic verification is lacking, but in a recent study cortical cotton wool plaques in a
sample from this family were documented (Houlden et al. 2000).  More than fifty
years later, a similar syndrome, characterized by the unusual combination of clinical
features of presenile dementia, cerebellar symptoms, and spastic paraparesis appeared
in Finnish patients (I, IV)  Neither spastic paraparesis nor cerebellar symptoms had
up until then been considered typical of AD.  Furthermore, although the neu-
ropathological lesions indicate that the disease in our patients falls within the spec-
trum of Alzheimer syndrome they do not unequivocally fulfill the established neu-
ropathological criteria for AD.  Consequently, we designated this disease “variant
Alzheimer’s disease with spastic paraparesis”.  Our southern Finnish pedigree includ-
ed 23 affected individuals of both sexes in four successive generations, which is com-
patible with autosomal dominant inheritance with full penetrance.  The oldest fami-
ly member known to be affected was born in 1860, but not enough data were availa-
ble on his parents or siblings to make predictions on their affectedness status.  It is
possible that some of his sibling may have passed the disease to their offspring, and
new patients from this family will turn up.  Furthermore, many individuals in the
fourth generation had not yet reached the age of typical onset.  There was an excess
of male patients (M/F ratio 16/7=2.28), and this skewed ratio may be due to the fact
that, by chance, there were more men than women both in the second (8/3) and third
(14/9) generations.  Mean age (±SD) at onset was 50.9±5.0 years, ranging from 40 to
61.  This is not early when compared to ages at onset in other PS-1 gene mutations
(from 29 to 64) (Haltia et al. 1994, Campion et al. 1996, Lendon et al. 1997, Cruts
and Van Broeckhoven 1998, Poorkaj et al. 1998).  In contrast to APP gene muta-
tions (St George-Hyslop et al. 1994) and similarly to other PS-1 gene mutations
(Van Broeckhoven et al. 1994, Kwok et al. 1997), the apoE genotype did not modu-
late age at onset in this family.  The patients died 5 to 12 years after onset, the main
cause of death being bronchopneumonia.  Affected men reached a slightly higher age
(62.3± 4.5 years) than affected women (58 ± 7.4 years).  At present, all living pa-
tients are receiving cholinesterase inhibitors, and postmenopausal estrogen therapy
has been recommended for women in this family.  The effect of these medications on
duration of the disease remains to be seen.
The disease is clinically characterized by a slowly progressive cognitive decline fi-
nally leading to dementia in all patients.  In the early stage of varAD, neuropsycho-
logical evaluation is of diagnostic value.  In addition to disturbed immediate and de-
layed recall, neuropsychological tests showed a distinctive profile.  Strong impair-
ment of  visuoconstructive and spatial skills were early and prominent features.  HSP
and varAD may have several clinical features in common, but in HSP dementia is a
rare finding.  In varAD the neuropsychological profile is different from that of sub-
cortical dementia, which is characteristic of those cases of HSP with dementia (Webb
et al. 1998, McDermott et al. 2000).  It is of further interest that in three families
with a mutation on chromosome 2p, HSP has been associated with cognitive impair-
ment and dementia (Webb et al. 1998, Heinzlef et al. 1998, White et al. 2000).  In
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questionable cases, neuropsychological examination may be of differential diagnostic
value.
In most cases, dementia was preceded by or appeared simultaneously with spastic
paraparesis, which was the most characteristic additional clinical feature of this vari-
ant AD, manifesting at 45 to 55 years of age.  At the early stage, patients experi-
enced walking difficulties and were frequently falling down.  Consequently, in most
patients, the initial referral to a neurologist had been because of impaired gait.  Be-
fore paraparesis, some but not all patients suffered from lower back pain, and two pa-
tients had retired because of severe chronic back pain before the manifestation of oth-
er symptoms.
From the diagnostic point of view, the clinical picture is crucial because routine
laboratory tests, neurophysiologic studies, or neuroimaging alone will not aid in the
diagnosis of varAD, although they are needed to exclude other neurological diseases.
In a number of  disorders in the literature, dementia and spastic paraparesis are the
main clinical findings.
Tropical spastic paraparesis is associated with HTLV-1 (type-C lymphotropic ret-
rovirus) infection and can be excluded by clinical features alone because painful par-
aesthesia in the legs and acute vasculitis do not  exist in varAD.  Vitamin B
12 
and vi-
tamin E deficiencies can be excluded by simple laboratory tests.  Amyotrophic lateral
sclerosis (ALS) when involving mainly the lower extremities is often diagnosed by
one or repeated EMG.  Normal-pressure hydrocephalus, central nervous system infec-
tions, multiple sclerosis, brain tumors, and spinal stenosis or tumors are verified by
neuroimaging (CT, MRI) and by cerebrospinal fluid (CSF) analysis.
FBD in its classic form is characterized by spastic tetra- and not paraparesis.
Furthermore some patients have sustained stroke-like episodes, and less constant
clinical features include headaches and “blackouts”(Plant et al. 1990) that are not
seen in varAD.  Other clinical findings in FBD are so similar to those in varAD that
molecular genetic analysis may be needed to confirm the clinical diagnosis.
However, neuroimaging may be useful because FBD is associated with extensive
periventricular white matter changes also visualized in MRI of the head (Plant et al.
1990). It is important to diagnose varAD because the patients can benefit from early
diagnosis in many ways, not only from early medical treatment.  Although the dis-
ease cannot yet be cured, more powerful treatments may be available in the future.
In addition, some family members at risk may consider presymptomatic genetic test-
ing in order to make reproductive and other personal choices.  This, however, re-
quires careful genetic counseling.
2.  NEUROPATHOLOGICAL PHENOTYPE (III)
Neuropathological investigations showed numerous, unusually distinct, large, round,
eosinophilic plaques in the cerebral cortex.  These “cotton wool” plaques (CWPs)
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were distinct from all types of plaques previously described as characteristic of AD
(Dickson 1997, Probst et al. 1991).  In contrast to diffuse plaques, CWPs were easily
detectable even in hematoxylin-eosin stained sections.  CWPs lacked a dense con-
gophilic core but were immunoreactive to Aβ.
They showed strong immunoreactivity for Aβ42/43, but only weak or no immu-
noreactivity for Aβ40.  In addition, biochemical analysis of cortical brain tissue dem-
onstrated markedly higher concentrations of Aβ42 and Aβ40 than in sporadic AD.
Despite the high levels of fibrillogenic Aβ42, no definite amyloid fibrils could be
found within CWPs by electron microscopy.  This phenomenon may be associated
with the paucity of macro-and microglial cells observed and the lack of complement
activation and amyloid P-component in CWPs.  CWPs have been identified in most
but not all varAD families (Table 2).  Even though CWPs are not included in the
neuropathological criteria of AD and are not typical of sporadic AD, in one study
scattered CWPs were reported to occur in occasional nonfamilial late-onset AD cases
(Dickson 2000).
Plaque morphology is important in the distinction between varAD, FBD, and
GSS.  CWPs do not occur in other diseases causing dementia and spastic paraparesis.
In FBD three types of plaques have been described (Plant et al. 1990, Revez et al.
1999), but none of these resembles the CWPs typical of varAD.  In addition to dif-
ferent morphology, plaques in FBD are immunoreactive to ABri but not to beta-
amyloid peptide (Plant et al. 1990, Revez et al. 1999) and white matter changes are
not seen in varAD, whereas amyloid plaques in GSS are multi-lobulated and show
immunoreactivity to PrP antibody (Masters et al. 2001).
Spastic paraparesis is a characteristic feature present in most varAD patients in
the present Finnish family.  Neuropathological data provide clues as to the etiology
of spastic paraparesis.  Patients show degeneration of the corticospinal tracts at the
level of the medulla oblongata and spinal cord.  The earliest description of  this kind
of degeneration in Alzheimer’s disease with spastic paraparesis is from the Belgian
family (van Bogaert et al. 1940), and later this finding was observed in a Japanese
patient (Aikawa et al. 1985).  In the present family, plaques were virtually absent
from the brain stem and spinal cord, and no significant amyloid angiopathy was
present.  This finding indicates that the primary lesions may well occur at cerebral
level.  Remarkably large conglomerates of CWPs were present in the interhemispher-
ic precentral cortex (paracentral lobule), corresponding to the motor representation of
the lower extremities, while the more lateral motor area was less affected.  A recent
study showed that extensive Aβ deposition occurred even in the primary motor cor-
tex of AD patients and was proposed to cause motor dysfunction in late stage of AD
(Suva et al. 1999).  Similarly, in GSS with spastic paraparesis the neuropathological
analysis does not show Aβ, but instead prion protein deposits in the cerebral cortex,
especially in the motor cortex (Ghetti et al. 1995).
In varAD, in addition to abundant CWPs in the interhemispheric motor cortex,
numerous NFTs and pronounced amyloid angiopathy were present in this area and
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may have further aggravated motor dysfunction.  However, amyloid angiopathy in
varAD involving the spinal cord vessels is not as extensive as in FBD where amyloid,
followed by ishemic damage to the cord parenchyma, is suggested to be responsible
for the spasticity, at least in part (Plant et al. 1990). In HSP, axonal degeneration oc-
curs in the tracts with the longest axons.  A “dying-back” mechanism has been sug-
gested beginning at the distal axon terminals and proceeding towards the cell body,
which eventually disappears (Behan and Maia 1974, McDermott et al. 2000).  In our
patients, axonal injury may be a factor contributing to spastic paraparesis because the
density of axons was reduced within the CWPs, and CWPs were particularly abun-
dant in the motor cortex.
Changes in the spinal cord are present in other familial diseases associated with
spastic paraparesis; however, Aβ plaques do not exist.  The major neuropathological
feature in FSP is axonal degeneration that is maximal in terminal portions of the
longest descending and ascending tracts within the spinal cord (Behan and Maia
1974), and in GSS there is degeneration with vacuolation and loss of myelin in the
pyramidal tracts in the brain stem and spinal cord (Ghetti et al. 1995).  There is de-
generation of corticospinal tracts in the spinal cord also in FBD (Plant et al. 1990).
In both varAD and FBD are plaques affecting the cerebellum and possibly causing
clinical symptoms.  However, the plaques affecting the cerebellum in FBD are most
frequently of the perivascular type (Plant et al. 1990).
3. GENOTYPE PHENOTYPE CORRELATIONS  (I, IV, V)
Unlike earlier examples of the ∆9 variant (Perez-Tur et al. 1995, Kwok et al. 1997,
Sato et al. 1998) this deletion was not caused by a splice acceptor site mutation.  The
disease of our patients was caused by a novel genomic deletion encompassing exon 9
of the PS-1 gene.
Previously, the combination of presenile autosomal dominant AD and spastic
paraparesis has been described in two more  Australian families (Kwok et al. 2000).
One of them  (AusAD1) is a 5.9kb genomic deletion in the PS-1 gene which removes
a portion of intron 8, the entire exon 9, and a portion of intron 9, while the other one
is a splice acceptor mutation (Kwok et al. 2000).
After the description of the ∆9 mutation in our varAD family, varAD caused by
PS-1 mutations has been reported in another British family (Houlden et al. 2000), in
a third Australian family (Taddei et al. 1998, Houlden et al. 2000), in a Scottish
family (Steiner et al. 2001), and in two families in two different states of the USA,
(Moretti et al. 2000, Farlow et al. 2000) (Table 2).  In varAD the presentation of
spastic paraparesis is variable, even within different members of the same family, as
in this Finnish family and in an Australian one (Smith et al. 2001).  In addition,
whole families have been reported with ∆9 splice mutations of PS-1 gene without
spastic paraparesis (Perez-Tur et al. 1995, Sato et al. 1998, Kwok et al. 2000).  An-
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other Finnish family with a genomic 4.6-kb deletion of exon 9 of the PS-1 gene was
recently described (Hiltunen et al. 2000).  In the pedigree there had been an affected
mother who had four children, three of whom became affected.  These patients did
not have spastic paraparesis, and CWPs were not found in the one available brain bi-
opsy from this family (Hiltunen et al. 2000).
It is noteworthy that  in Alzheimer’s disease spastic paraparesis has been reported
only in association with PS-1 gene mutations (Table 2) but not in APP or PS-2 gene
mutations. It is becoming increasingly important to identify distinctive clinical fea-
tures of subtypes of AD so that molecular genetic investigations can focus on the
right gene.  The combination of spastic paraparesis or brisk tendon reflexes of the
lower extremities, presenile dementia, and cerebellar signs should alert the clinician
to consider varAD and focus molecular genetic studies on the PS-1 gene.
4.  PATHOGENETIC IMPLICATIONS
Several neuropathological findings associated with varAD may be of significance for
the understanding of the pathogenesis of AD in general.
Severe cytoarchitectural changes are associated with varAD.  CWPs were fre-
quent in the entorhinal cortex and hippocampus  and especially abundant in the
subiculum.  The expansive CWPs displaced neurons and even interrupted and dis-
torted the granular cell layer of the dentate gyrus as well as the pyramidal cell band
of the hippocampus.  It has been suspected that lesions of the entorhinal cortex and
other limbic structures, potentially important in the genesis of memory impair-
ments, may serve to disconnect the hippocampus and the neocortex (Hyman et al.
1984).  The functional role of the distorted cytoarchitecture in the entorhinal cortex
and hippocampus in varAD and their possible contribution to dementia need further
investigation.
In confocal microscopy the axons seemed either to wind around the CWP or to
degenerate on entering into the CWP.  It is likely that these findings are indicators
of axonal damage and may be associated with functional disturbances.  A previous
study has indicated that in sporadic AD neurites are disrupted within a subset of Aβ
deposits (Knowles et al. 1998).  Neurites that pass through Aβ deposits lose their
normal straight configuration, and this change in geometry has marked consequences
in terms of the signal transduction properties of dendrites (Knowles et al. 1999).
According to the amyloid cascade hypothesis of AD, the β-amyloid peptide is
toxic to nerve cells and thereby is the main cause of the neurodegeneration in AD
(Hardy et Higgins 1992).  Our observations in varAD constitute a strong argument
against this classic amyloid cascade hypothesis in its simple reading.  The presence of
dominant CWPs without amyloid cores rather than neuritic plaques in our demented
patients supports the view that the extracellular, poorly soluble, congophilic amyloid
plaques are not the only initiators of neurodegeneration in AD.  However, the excep-
53
tionally high production of Aβ42/43 in varAD is likely to be of pathogenetic signifi-
cance, and therefore we and others (Yankner 1998, Steiner et al. 2001) suggest that
Aβ is neurotoxic at a stage prior to amyloid fibril formation.
CONCLUSIONS
On the basis of the present study, the following conclusions can be drawn:
1.  Twenty-three affected individuals with presenile dementia were identified in four
successive generations of a Finnish family.  The distribution of affected individuals
within the pedigree was compatible with an autosomal dominant mode of inherit-
ance with full penetrance.  The mean age (±SD) at onset was 50.9±5.0, ranging from
40 to 61 years.  Memory impairment was the neurological sign shared by all pa-
tients.  Spastic paraparesis was the second most common clinical feature of this vari-
ant AD.  It was often the first symptom of the disease preceding dementia.  In some
patients, however, spastic paraparesis appeared simultaneously with dementia where-
as it was preceded by dementia in one case only.  It is noteworthy that spastic para-
paresis was present in most but not all patients.  Besides memory deficits, early and
prominent impairment of visuoconstructive functions was characteristic.  Most af-
fected individuals showed clumsiness of the hands and dysarthria suggesting cerebel-
lar involvement.  The combination of spastic paraparesis and dementia constitutes a
distinct syndrome with the frame of Alzheimer’s disease designated variant AD with
spastic paraparesis.  Any patient with spastic paraparesis should be tested for cogni-
tive function.
2.  The primary and association cortices and hippocampus of the affected individuals
showed a profusion of eosinophilic roundish structures with distinct borders termed
“cotton wool” plaques (CWPs).  These unusual plaques have not been described earli-
er in AD or in any other neurodegenerative diseases.  CWPs were immunoreactive
for Aβ42/43 but weakly or not at all for Aβ40 isoforms of the amyloid β peptide.
However, the CWPs were devoid of a congophilic core, and fibrillar amyloid could
not be seen within them by electron microscopy.  In addition to the CWPs, degener-
ation of the lateral corticospinal tracts was a characteristic feature.  Diffuse and non-
neuritic cored amyloid plaques but no CWPs occurred in the cerebellum.  Our obser-
vations in varAD constitute a strong argument against the classic amyloid cascade
hypothesis in its simple reading.  The predominance of CWPs without amyloid cores
and definite amyloid fibril formation in the cerebral cortex of demented patients sug-
gests that the abnormal processing of APP resulting in the accumulation of Aβ is
deleterious at a stage prior to amyloid fibril formation.
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3.  Our molecular genetic analysis began by sequencing of the exons and the imme-
diate flanking intronic regions of the PS-1 gene from genomic DNA amplified by
PCR.  This approach, however, did not disclose the mutation, which was first identi-
fied as a deletion of exon 9 through sequencing of PCR-amplified cDNA obtained
from lymphoblastoid mRNA.  By use of intronic primers flanking exon 9, the muta-
tion was eventually defined as a 4,555kb genomic deletion between exons 8 and 10
of the PS-1 gene.  This is the first genomic deletion mutation associated with AD.
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Table 2   Families with varAD causing spastic paraparesis and presenile dementia, or having exon 9
deletion
Author and year of spastic Nationality/code for Type of  PS-1 mutation Neuropathology
publication paraparesis the family
van Bogaert 1940 Belgian/CO Not known Cotton wool
Houlden et al. 2000 yes plaques
Perez-Tur et al. 1995 no British/F74 ∆9 (splice site) Nearly typical
Mann et al. 1996
Kwok et al.  2000 yes Australian/EOAD1/ ∆9 (genomic deletion) Cotton wool
Smith et al. 2001 AusAD-1 plaques
Aus-1 Corticospinal
tract
degeneration
Kwok et al. 1997 no Australian/EOAD2/ ∆9 (splice site; G to A) Typical
Kwok et al. 2000 AusAD-2
Kwok et al. 1997 yes Australian/EOAD3/ ∆9 (splice site; G to T) Not reported
Kwok et al. 2000 AusAD-3
Sato et al. 1998 no Japanese ∆9 (splice site) Typical
but severe
I    2000 yes Finnish/Finn2∆9 ∆9 (genomic deletion) Cotton wool
III 2001 plaques
IV 1998
V  1999
Taddei et al. 1998 yes Australian/D P436Q Cotton wool
Houlden et al. 2000 plaques
Hiltunen et al. 2000 no Finnish ∆9 (genomic deletion) Cotton wool
plaques not
present in the
one cortical
biopsy sample
taken
Moretti et al. 2000 yes American (Michigan) insertional mutation in Not reported
putative intracellular
loop between
transmebrane domains
2 and 3
Farlow et al. 2000 yes American (Indiana) aminoacid change at Typical, but
codon 261 (valine to severe cerebral
phenylalanine) amyloid
angiopathy and
degeneration of
lateral
pyramidal tracts
Houlden et al. 2000 yes British/EB DelIM (from exon 4) Cotton wool
plaques
Steiner et al. 2001 yes Scottish ∆I83/∆M84 Cotton wool
(within TM1) plaques
58
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